INHIBITORS OF CYCLIN-DEPENDENT KINASES AS CANCER THERAPEUTICS

Authors: Steven R. Whittaker[1], Aurelie Mallinger[1,2], Paul Workman[1,2] and Paul A. Clarke[1,2]*

[1]Division of Cancer Therapeutics and [2]Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP.

***Corresponding author:** paul.clarke@icr.ac.uk

Running title: CDK inhibitors

Key Words: Cyclin-dependent kinase, cell cycle, transcription, inhibitor

ACKNOWLEDGEMENTS

This work was supported by Cancer Research UK (grant numbers C309/A11566, C368/A6743 and A368/A7990). We acknowledge Cancer Research UK funding to the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research. Paul Workman is a Cancer Research UK Life Fellow. We thank Nicky Evans for editorial assistance and our many colleagues and collaborators for helpful discussions.

CONFLICT OF INTEREST

PAC, SRW, AM and PW are employees of The Institute of Cancer Research, which has a commercial interest in the development of CDK inhibitors.

ABBREVIATIONS

AML, acute myeloid leukemia; CAK, CDK-activating kinase; CDK, cyclin-dependent kinases; CLL, chronic lymphocytic leukemia; CT, RNA polymerase II C-terminal domain;

DLT, dose-limiting toxicities; DSIF, DRB-sensitivity inducing factor; ER, estrogen Receptor; LRP, low-density receptor-related lipoproteins; MAPK, mitogen-activated protein kinase; RB, retinoblastoma protein; NELF, RNA polymerase II–associated negative elongation factor; PFS, progression free survival; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase.

ABSTRACT

Over the past two decades there has been a great deal of interest in the development of inhibitors of the Cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer. CDKs have now been shown to regulate other processes, particularly various aspects of transcription. The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers. The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors. However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest. Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER+/HER2- advanced breast cancer. Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compounds that have allowed exploration of individual CDKs as cancer targets and the determination of their potential therapeutic windows. Biomarkers that allow the selection of patients likely to respond are now being discovered. Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors in the clinic. This suggests that the selective inhibitors may be best used combined with standard of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.

Table of contents

1. Introduction

The notion of the cell cycle and its regulatory restriction points was first proposed in the 1970s and early 1980s. The machinery components associated with this process were identified and characterized through many genetic and biochemical studies, mainly in yeast, but also in sea urchin, xenopus, and eventually higher eukaryotic cells (Nurse, 2000). The core of this work resulted in the identification of the CDKs and their partner cyclins for which the Nobel Prize in Physiology and Medicine was awarded to Hartwell, Hunt and Nurse in 2001. The regulation of the growth and division of cells came to the attention of the biomedical research community when it became clear that unconstrained proliferation, in part due to a loss of cell cycle regulation, played a key role in the initiation and progression of cancer. More recently, sustained proliferation through the deregulation of cell cycle control has been recognized as one of the key hallmarks of cancer (Hanahan & Weinberg, 2011), and our understanding of how specific CDKs regulate transcription and maintain the oncogenic state has advanced considerably. This has led to considerable efforts to develop CDK inhibitors as cancer therapeutics, which is the subject of this review. Here we will review the role of CDKs in cancer and particularly those for which inhibitors have currently been identified. These inhibitors include the early non-selective inhibitors that suffered from toxicity and poor efficacy, but more importantly the more recent developments in selective CDK inhibitors that have led to the approval of palbociclib for the treatment of breast cancer.

The CDK family

The human genome encodes 26 serine/threonine protein kinases that form a CDK and CDK-like branch of the CMGC subfamily of the human kinome; of these, 21 are classified as CDKs (Malumbres, 2014; Malumbres, et al., 2009). The CDKs have specific or redundant roles in many aspects of cell growth, proliferation and transcriptional regulation in response to extracellular and intracellular signals. The evolutionary relationships

between these CDK subfamilies have been identified (**Figure 1**) and indicate that the CDK subfamilies can be divided into subfamilies that directly or indirectly regulate the cell cycle (CDKs1-6, 11 and 14-18) or transcription (CDKs7-13, 19 and 20).

Similar to all protein kinases, the CDKs have a two-lobed structure comprising a beta sheet-rich amino terminus and an alpha helix-rich carboxy terminus, with the active site sandwiched between the two (Malumbres, 2014; Malumbres, et al., 2009). Members of the CDK family have a conserved catalytic core containing an ATP-binding pocket, a cyclin subunit - binding domain and an activating T-loop motif. Collectively these features participate in CDK activation. The CDKs are constitutively expressed but, as their name suggests, typically require association with a cyclin subunit in order to become active (**Figure 1**). Regulation of the CDKs predominantly occurs by means of the control of cyclin production and destruction, as cyclin binding displaces the T-loop, exposing the substrate binding site and realigning critical residues in the active site that primes the kinase for activity (Jeffrey, et al., 1995; Russo, Jeffrey, & Pavletich, 1996). In addition to the regulatory effects of cyclin-binding, phosphorylation also coordinates the activity of the CDKs in response to various stimuli (Mueller, Coleman, Kumagai, & Dunphy, 1995). Most CDKs have inhibitory phosphorylation sites in the P-loop of the active site which when phosphorylated interfere with ATP binding at the catalytic site (Mueller, et al., 1995). Some CDKs also have activating phosphorylation sites in their T-loops that are substrates of CDK-activating kinases that includes other CDKs. Phosphorylation of these T-loop sites enhances substrate binding and complex stability, promoting full CDK activation (Russo, et al., 1996)..

2. Cell cycle regulation by CDKs

The cell cycle has 5 distinct phases during which cells either have the capacity to grow (G1 and G2 phases), replicate their DNA (S phase), divide by mitosis (M phase) or can

cease to proliferate and enter quiescence (G0 phase)**(Figure 2)**. Cell cycle progression is governed by the activities of particular CDKs and interaction with their regulatory cyclin partners (Sherr, 1996; van den Heuvel & Harlow, 1993). The function and role of the key individual CDKs that regulate cell cycle progression are described in detail in the sections below.

2.1. CDK4/6

In normal cells the cell cycle is initiated when growth factor receptors are stimulated, propelling cells from a quiescent, non-cycling G0 state into an active cycling state (**Figure 2**). The mitogenic stimulation of RAS and RHO GTPase-dependent pathways, mTOR activation and steroid receptor-activation can all induce entry to the cell cycle (Aktas, Cai, & Cooper, 1997; Marshall, 1999; Rodgers, et al., 2014). Of these, the role of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) lipid kinase pathway has been the most extensively characterised. ERK1/2 activation promotes the transcription of the D-type cyclins, commonly through the activity of FOS- and JUN-related transcription factors (Balmanno & Cook, 1999; Lavoie, L'Allemain, Brunet, Muller, & Pouyssegur, 1996). The D-type cyclins associate with CDK4 and CDK6 to generate active kinase complexes that directly phosphorylate the retinoblastoma protein (RB) (Peeper, et al., 1997; Sherr, 1996). The predominant view is that this causes the dissociation of both HDAC1 and the E2F transcription factors from RB, allowing histone acetylation and activated transcription of many genes, including cyclin E (Blais & Dynlacht, 2007; H. S. Zhang & Dean, 2001) (**Figure 2**). Early studies showed that RB exists in a hypo-phosphorylated state in quiescent cells and that its phosphorylation in response to mitogens is associated with progression through the cell cycle (Classon & Harlow, 2002). While it was originally suggested that distinct CDK/cyclin complexes progressively target specific phosphorylation sites on RB, such as T821 by CDK2 and T826 by CDK4, this has not been comprehensively addressed (Mittnacht,

Lees, Desai, Harlow, Morgan, & Weinberg, 1994; Zarkowska & Mittnacht, 1997). More recently, it has been proposed that RB may be mono-phosphorylated by CDK4/6 activity on any one of 14 sites (Narasimha, et al., 2014). Upon CDK2/cyclin E activation, the remaining sites are phosphorylated by CDK2 to give hyper-phosphorylated RB, to fully relieve suppression of E2Fs and permit cell cycle progression. Consequently, it may not be possible to use specific RB phosphorylation sites to monitor the activity of specific CDKs, rather the loss of mono-phosphorylated RB could be attributed to impaired CDK4/6 activity and loss of hyper-phosphorylated RB due to lack of CDK2 activity. In any case, RB remains phosphorylated throughout the S, G2 and M phases, and at the end of mitosis it is dephosphorylated by protein phosphatase 1 (Malumbres & Barbacid, 2009). Hence, there is very a strong link between the phosphorylation status of RB and cellular replication.

CDK4/6 also phosphorylate the transcription factor FOXM1, resulting in its activation and stabilization (Anders, et al., 2011). FOXM1 shares many of the functions of CDK4/6: it promotes the G1/S transition, suppresses senescence and is involved in tumorigenesis (Kalinichenko, et al., 2004; M. Liu, et al., 2006; I. C. Wang, et al., 2005; I. C. Wang, et al., 2008). Notably, FOXM1 is required for the expression of key genes that regulate G1/S phase progression, such as *CCNE1*, *CCNE2*, *E2F2*, *MCM2*, *MCM10* and *CDT1* (Anders, et al., 2011).

Genetic studies found most mouse cells proliferate in the absence of Cdk4 (Rane, et al., 1999; Tsutsui, et al., 1999), potentially because Cdk6 is able to compensate for the loss. Similarly, Cdk6 ablation is well tolerated: mouse embryos develop normally with modest impairment of haematopoiesis. In contrast, dual Cdk4/Cdk6 knockout embryos generally fail to survive to birth; those that are born die within a few hours, likely because of the limited proliferation of erythroid progenitors resulting in a lack of red blood cells (Malumbres, et al., 2004). However, cells from other tissues in these embryos proliferate

normally, indicating that Cdk4/6 are primarily required for haematopoesis in early development. Simultaneous knockout of the D cyclins *Ccnd1*, *Ccnd2* and *Ccnd3* yielded comparable results to knockout of Cdk4/Cdk6 (Kozar, et al., 2004). Ablation of both Cdk4 and Cdk2 in adult mice is well tolerated and even highly proliferative tissues (oesophagus or intestine) are unaffected (Barriere, et al., 2007). The phenotype of conditional double knockout Cdk4/Cdk6 mice in adulthood and the effects on homeostasis have yet to be reported, but based on mouse embryonic fibroblasts derived from Cdk4/6 knockout mice, such events are anticipated to be tolerated in adult tissues (Malumbres, et al., 2004). Confidence in selective pharmacological CDK4/6 inhibition being well tolerated clinically has been boosted by such studies, and suggested the potential for a therapeutic window between tumor and normal tissue.

2.2. CDK2

The transcriptional program induced following the activation of E2F1 and FOXM1 by CDK4/6 includes increased expression of genes encoding cyclins E1 and E2. Further phosphorylation of RB (**Figure 2**) results from the newly synthesized cyclins E1 and E2 binding and activating, CDK2. E2F1 also stimulates the transcription of genes coding for proteins involved in DNA replication, including the expression of cyclin A, which accumulates during S phase and becomes the predominant cyclin bound to CDK2 (Harbour, Luo, Dei Santi, Postigo, & Dean, 1999; Helin, 1998). The activity of CDK4/6 and CDK2 coordinate progression into S phase, termed the 'restriction point', where the cell is no longer dependent on mitogens to complete the current cell cycle (**Figure 2**). CDK2 is capable of phosphorylating a number of additional substrates including NPAT, CDC6 and E2F1 (Asghar, Witkiewicz, Turner, & Knudsen, 2015). Specifically, while CDK2/cyclin E complexes promote entry into S phase through phosphorylation of RB and NPAT, CDK2/cyclin A complexes help to terminate S phase, by phosphorylating CDC6 and E2F1. The cyclin A protein remains present in the cell until mitosis when it is

degraded in an APC-dependent manner prior to anaphase (Furuno, den Elzen, & Pines, 1999; Pagano, Pepperkok, Verde, Ansorge, & Draetta, 1992).

Cdk2 null mice are viable, suggesting that Cdk2 has little effect on the proliferation and survival of most cell lineages. In fact, the main phenotype displayed by Cdk2 null mice is defective gamete development attributed to impairment of the first meiotic division (Ortega, et al., 2003). These data are somewhat complemented by studies examining the effect of CDK2 inactivation in colon cancer cell lines, which have shown that inhibition of CDK2 through expression of $p27^{KIP1}$, DN-CDK2 or antisense mediated depletion does not inhibit cell proliferation (Tetsu & McCormick, 2003). However, recent data manipulating the gatekeeper residue in CDK2 to allow specific inhibition by adenine analogs resulted in reduced proliferation and indicates CDK2 may be required for cell proliferation in some circumstances (Merrick, et al., 2011). Consistent with this, loss of Cdk2 and/or cyclin A2 has been shown to inhibit the proliferation of mouse embryonic fibroblasts, promote premature senescence and delay tumorigenesis in a mouse liver cancer model (Gopinathan, et al., 2014). Notably, elevated CDK1 kinase activity may play a compensatory role following ablation of cyclin A2, suggesting that dual targeting of CDK1 and CDK2 may be a necessary strategy for cancer therapy. Currently our understanding of the precise contexts where CDK2 is required for cell proliferation is incomplete and further advances in this area would help direct the future development of this class of agents.

2.3. CDK1

Cyclin A also binds CDK1 during the late S/G2 phase. Activation of the transcription factors FOXM1 and FOXK2 by CDK1/cyclin A followed by CDK1/cyclin B promotes the expression of genes involved in mitotic progression (Laoukili, et al., 2008; Marais, et al., 2010; Sadasivam, Duan, & DeCaprio, 2012)(**Figure 2**). Cyclin B mRNA and protein

increases during the G2 phase of the cell cycle, but is destroyed during mitosis at the metaphase-anaphase transition. Phosphorylation of the cyclin B cytoplasmic retention sequence, prior to mitosis, promotes the translocation of this protein to the nucleus and reduces its nuclear export. CDK1/cyclin B has a number of nuclear substrates: these complexes are known to phosphorylate lamin, leading to nuclear envelope breakdown (Peter, Nakagawa, Doree, Labbe, & Nigg, 1990a, 1990b), and nucleolin, regulating nuclear fragmentation and organization (Belenguer, Caizergues-Ferrer, Labbe, Doree, & Amalric, 1990; Peter, et al., 1990a). Thus, CDK1 activity is a major determinant of cell cycle progression, ensuring that critical events occur in the correct sequence so that cellular replication proceeds with high fidelity.

CDK1 has also been implicated in the DNA damage response. BRCA1 is a direct target of CDK1 kinase activity and mutation of the CDK1 phosphorylation sites on BRCA1, or a loss of CDK1 activity, reduces the number of BRCA1 foci. As a result, cells are sensitized to DNA damaging agents (Johnson, et al., 2009). This finding led to the hypothesis that CDK1 inhibition would induce a BRCA-deficient-like phenotype and that inhibition of PARP would present a novel therapeutic strategy for BRCA-wildtype cancers (Johnson, et al., 2011). Excitingly, this approach has shown selectivity for transformed cells and has been well tolerated in mouse models of $Kras^{G12D}$, $Trp53^{L/L}$ lung adenocarcinoma (Johnson, et al., 2011).

Genetic studies of Cdk1 ablation in mice have demonstrated that Cdk1 is required for cell cycle progression and that Cdk1 can functionally compensate for the loss of CDKs 2, 3, 4 and 6 by forming active complexes with cyclins D and E to drive the cell cycle. Knocking out Cdk1 yielded no viable homozygous mice or early stage embryos (E1.5-E2.5) (Santamaria, et al., 2007). Interestingly, an interaction between CDK1 and cyclins D and E is only observed in the absence of expression of the other CDKs, suggesting that phenotypic lethality may not occur if CDK1 were to be targeted by small-molecule

inhibitors. However, given that CDK1 appears essential for cell proliferation, compounds that inhibit CDK1 directly, or indirectly via the depletion of cyclins A2 and B1, may display toxicity that limits their clinical utility (Brandeis, et al., 1998; Murphy, et al., 1997).

3. Transcriptional regulation by CDKs

The polymerase responsible for transcribing all protein-coding genes is RNA polymerase II. RNA polymerase II catalyzes the transcription of histone-associated genomic DNA, which is wrapped around nucleosomes and can be covalently modified to regulate the access of the transcriptional apparatus to the DNA (Li, Carey, & Workman, 2007). For gene-specific transcription to take place RNA polymerase II has to be recruited to, and then exit, the gene's promoter that is then and followed by productive transcription that elongates the mRNA. This is a complex process requiring chromatin modification, the recruitment of sequence-specific transcription factors and post-translation modification of the transcriptional machinery.

RNA polymerase II is unique among the cellular polymerases as its largest subunit has a C-terminal domain (CTD) with an extended repeat comprised of a YSPTSPS heptapeptide that is present in a copy number ranging from 26 in budding yeast to 52 in humans (Corden, 2013; Eick & Geyer, 2013; Fisher, 2012; Jasnovidova & Stefl, 2013; Jeronimo, Bataille, & Robert, 2013; Jeronimo, Collin, & Robert, 2016). The CTD is not required for catalytic activity of the polymerase, but instead plays a key role in RNA processing and chromatin organization by acting as a landing pad for regulatory proteins, allowing the coordination of transcriptional and cotranscriptional events (Jeronimo, et al., 2013). The consensus heptapeptide can be phosphorylated at Tyr1, Ser2, Thr4, Ser5 and Ser7 and is a target of many kinases and phosphatases and post-translational modifying enzymes (Jeronimo, et al., 2016). With greater understanding of the role of the CTD it has become clear that specific and temporal post-translational modifications of the CTD regulate the

activity of RNA polymerase II globally, and in a gene-specific manner, in response to environmental stimuli or the cellular state (Bataille, et al., 2012; Drogat & Hermand, 2012; Mayer, et al., 2010). Studies in yeast have determined a cycle of regulation (**Figure 3**). When RNA polymerase II is recruited to promoters it becomes phosphorylated on Ser5 and Ser7 before initiating transcription. Following the initiation of transcription Ser5 phosphorylation decreases while Ser2 and Tyr1 phosphorylation increases. When transcription terminates Tyr1 is the first residue to be dephosphorylated, closely followed by Ser5, Ser7 and Ser2. A similar pattern of CTD phosphorylation occurs in other higher eukaryotes (**Figure 3**), although possibly with the exception of the modification of Tyr1 (Corden, 2013; Eick & Geyer, 2013; Jasnovidova & Stefl, 2013; Jeronimo, et al., 2013; Jeronimo, et al., 2016). The multiple kinases that phosphorylate the CTD have been identified and, of relevance to this review, include CDKs (Jeronimo, et al., 2016).

3.1. CDK7

The active CDK7 enzyme binds cyclin H and a ring finger protein MAT1 to form a subcomplex of the 10-subunit general transcription factor (TFIIH) complex. This complex has helicase, ATPase and protein kinase activity and is required for the earliest stage of transcription initiation (**Figure 3**)(Fisher, 2012). The first step in activating transcription is the formation of the pre-initiation complex that is required for promoter recognition and DNA unwinding. This requires RNA polymerase II to interact with multiple proteins, including the large multi-subunit Mediator complex and several general transcription factors, and may happen in a step-wise manner (Gupta, Sari-Ak, Haffke, Trowitzsch, & Berger, 2016). The binding of TFIID to the core promoter initiates the process and is followed by recruitment of additional general transcription factors and RNA polymerase II. This also involves structural rearrangements as the pre-initiation complex is initially in a ‘closed’ confirmation from which initiation cannot occur (Gupta, et al., 2016). The TFIIH complex is the last to be recruited and its helicase activity opens approximately one

helical turn of DNA at the transcription start site. This leads to a conformational change that 'opens' the complex and positions the single strand DNA in the RNA polymerase II active site. The next step requires the kinase activity of the CDK7 subunit in the TFIIH complex to drive the escape of the polymerase from the promoter by breaking its interactions with other complex members. CDK7 primarily phosphorylates RNA polymerase II CTD Ser5, but can also phosphorylate Ser7 (Jeronimo, et al., 2016). Generally the RNA polymerase transcribes around 20-100 bases downstream of the promoter before pausing and in another regulatory process loses the remaining components of the initiation complex, yielding a fully functional elongation complex.

CDK7 may also influence cell cycle control by functioning as a CDK-activating kinase (CAK) and phosphorylating cell cycle CDKs, such as CDK1 and CDK2 (Fisher, 2012). *In vitro*, CDK7 can phosphorylate the T-loops of both cell cycle and transcriptional CDKs. Acute inhibition of CDK7 in human colorectal cancer cells prevented activation of CDK1 and 2, while genetic analyses in flies and worms implicated CDK7 in CDK1 activation. Cdk7 or Mat1 mouse knockouts are not viable as the loss of either gene is embryonically lethal (Ganuza, et al., 2012; Rossi, et al., 2001). Cells cultured from *Mat1*$^{-/-}$ mice were characterized by an inability to enter S phase and exhibited reduced phosphorylation of Ser5 and also Ser2 of the RNA polymerase II CTD. Despite this reduced phosphorylation knockout cells retained transcriptional activity, suggesting that residual Ser5 phosphorylation mediated by additional CTD kinases was sufficient to maintain transcription (Rossi, et al., 2001). Similar results were detected with Cdk7 deficient cells where Cdk7 was generally indispensible for proliferation, but not essential for global transcription. In adult Cdk7 conditional knockout models loss of Cdk7 had little effect in tissues with low levels of proliferation, in contrast, tissues with elevated cell turnover exhibited age-related loss of progenitor cells. At the molecular level loss of Cdk7 in mouse embryo fibroblasts resulted in reduced T-loop phosphorylation of CDKs suggesting

that Cdk7 was acting as a CAK and expression of $Cdk1^{T161E}$ and $Cdk2^{T160E}$ T-loop phosphomimetic proteins partially restored proliferation.

Over-expression of CDK7, and its cofactors cyclin H and MAT1, was recently reported in a cohort of >900 breast cancer samples. Expression of CDK7/cyclin H/MAT1 was greater in estrogen Receptor (ER) -positive breast cancer tumors versus ER-negative tumors. Loss of CDK7 activity resulted in decreased phosphorylation of ER^{SER118}, suggesting that CDK7 is responsible for ligand-dependent phosphorylation of this site and promotes ER activity. Hence, CDK7 inhibition is proposed as a potential treatment for ER-positive, high ER^{SER118} and CDK7-expressing breast cancers (Patel, et al., 2016). CRISPR/Cas9 mediated gene editing of CDK7 has also identified a dependency of triple-negative breast cancer (Y. Wang, et al., 2015). The cancer cells die by apoptosis as they are addicted to CDK7 and are dependent on an "achilles cluster" of survival genes regulated by super-enhancers that require CDK7. The CDK7 knockout studies suggest that CDK7 inhibitors would be tolerated for short periods, but may have effects on stem cell populations if given systemically resulting from cell cycle effects for an extended period of time (Ganuza, et al., 2012).

3.2. CDK9

Following transcription initiation, the pausing of the RNA polymerase II complex proximal to the promoter is an opportunity for mRNA processing and for the recruitment of further transcription factors (**Figure 3**). The transition to productive elongation requires the pTEFb elongation factor complex. This complex has a CDK9 subunit that phosphorylates the polymerase CTD at Ser2, and also the RNA polymerase II–associated negative elongation factor (NELF) and DRB-sensitivity inducing factor (DSIF) (**Figure 3**). Phosphorylation of the CTD at Ser5 by CDK7 is required for pTEFb recruitment and

therefore inhibition of CDK7 can lead to reduced Ser2 phosphorylation by CDK9 (Larochelle, et al., 2012; Viladevall, et al., 2009).

CDK9 is ubiquitously expressed and forms heteromer complexes with cyclins T1, T2a, T2b and K **(Figure 1)**. In addition to associating with a cyclin, CDK9 must be phosphorylated on activation-loop-residue Thr186 phosphorylated in order to function. Studies indicate that a number of different kinases can activate CDK9 and suggest that the cellular context of CDK9 critically influences the mode of its activation (Sonawane, et al., 2016). CDK7 may directly activate CDK9, as there is evidence that CDK7 can phosphorylate the T-loop of CDK9 (Larochelle, et al., 2012; Viladevall, et al., 2009). However, data from CDK7 knockout mice suggest CDK9 can also be activated by other protein kinases. RNAi screening identified CAMK1D as a kinase that phosphorylates CDK9 at Thr186, while the atypical kinase BRD4 can inhibit or activate CDK9 by phosphorylating it at Thr29 on the P-loop or Thr186 on the T-loop respectively (Devaiah & Singer, 2012; Ramakrishnan & Rice, 2012).

CDK9 has been proposed as a therapeutic target in cancer as it influences the expression of a number of genes encoding short-lived anti-apoptotic proteins associated with drug resistance (Bose, Simmons, & Grant, 2013; S. Wang & Fischer, 2008). A study using a phenotypic screen to identify the effects of inhibiting transcriptional CDKs found that transient inhibition of CTD phosphorylation induced caspase-dependent apoptosis, but only in transformed cells (S. Wang, et al., 2010). Silencing of CDK9 expression by shRNA or siRNA results in a range of phenotypes, with CDK9 knockout having contrasting effects on proliferation and cell death depending on use as a mono- or combined therapy (Garriga, Xie, Obradovic, & Grana, 2010; C. H. Huang, et al., 2014; F. Lam, et al., 2014; Storch & Cordes, 2016; Z. Q. Wang, et al., 2014). In immortalized normal fibroblasts, primary human astrocytes or glioblastoma cells CDK9 inhibition significantly influenced the gene expression pattern, but the number genes affected by dominant-negative *CDK9*

expression or *CDK9* siRNA silencing was small and cell line dependent (Garriga, et al., 2010). These observations provide a degree of validation for CDK9 as a therapeutic target that may affect sub-set of tumor specific genes required for proliferation and survival. However, a recent study exploring components of the CDK9 interactome identified many proteins with roles in processes such as splicing and translation, downstream of the accepted locus of CDK9 function (J. Yang, et al., 2015). In addition, BRD4, that targets the P-TEFb complex to the promoters of many genes, mediates a compensatory mechanism that is activated upon CDK9 inhibition. Hence, the therapeutic potential of CDK9 inhibitors may only be revealed with concomitant BRD4 inhibition (Sonawane, et al., 2016).

3.3. CDK12/13

In higher eukaryotes, CDK9 is often referred to as the CTD Ser2 kinase, and the requirement for CDK9 for efficient transcriptional elongation has led to an assumption that Ser2 phosphorylation is critical for overcoming the early elongation block. Moreover, CDK9 is often presented as a kinase that essentially merges the activities of the yeast Bur1 and Ctk1 protein kinases (Bartkowiak & Greenleaf, 2011; Drogat & Hermand, 2012). However, several other Ser2 kinases have now been identified including CDK12 and its close homolog CDK13 (Bartkowiak, et al., 2010). Based on work carried out in Drosophila and yeast, it has been suggested that CDK9 phosphorylates Ser2 early on in transcription, before passing on this role to CDK12, which phosphorylates Ser2 for the majority of the elongation phase (Jeronimo, et al., 2016). However, knockout or chemical inhibition experiments have had, at best, modest effects on global CTD phosphorylation, which can be interpreted as CDK12 either having no importance in human CTD Ser2 phosphorylation or having functional redundancy with CDK13 or other Ser2 kinases (Bartkowiak, Yan, & Greenleaf, 2015; Jeronimo, et al., 2016). One explanation is that the role of CDK12 in CTD phosphorylation is gene-specific. Deletion of mouse Cdk12 is

embryonically lethal as a result of pluripotent cells losing their capacity for self-renewal and dying by apoptosis (Juan, Lin, Chen, & Fann, 2016). At the molecular level this was due to reduced expression of genes associated with self-renewal of stem cells. CDK12 has also been associated with the regulation of a subset of genes required for the cellular response to DNA damage (Blazek, et al., 2011). This was also observed in the CDK12 knockout model that exhibited reduced expression of gene encoding DNA damage repair proteins (Juan, et al., 2016). This may impact on the maintenance of pluripotency as mouse embryonic cells frequently have elevated DNA breaks that occur during replication and their repair is critical for successful embryonic development. Importantly, mice deficient for Rad50, Rad51, Atr and Brca1 have similar phenotypes to the Cdk12 knockout mice (Juan, et al., 2016).

Proteomic and biochemical studies of CDK12 partners and substrates identified interactions between CDK12 and several RNA processing factors found in subnuclear domains enriched with splicing factors (Bartkowiak & Greenleaf, 2015; H. H. Chen, Wang, & Fann, 2006; Eifler, et al., 2015; Ko, Kelly, & Pines, 2001; Liang, et al., 2015). Loss of CDK12 and CDK13, or their associated cofactor cyclin K, not only impeded the progress of RNA polymerase II, but also RNA processing. CDK12 binds to exon-junction complexes containing arginine–serine rich splicing factors, and the loss of CDK12 leads to mRNA splicing defects (Bartkowiak & Greenleaf, 2015). Furthermore, the recruitment of factors involved in the cleavage and polyadenylation of the 3'-end of mRNA takes place at the same time as CTD Ser2 phosphorylation and is dependent on CDK12 function. Finally, CDK12 depletion leads to a loss of Ser2 phosphorylation, reduced recruitment of splicing factors, and 3'-end processing defects in the transcripts of genes such as *FOS* and *MYC* (L. Davidson, Muniz, & West, 2014; Eifler, et al., 2015).

Considering that CDK12 regulates the expression of several cancer-related genes, such as *FOS* and *MYC*, it is not surprising that the deregulation of CDK12 has been identified in

cancerous tissues. For example, breast cancers have *CDK12* and *ERBB2* genes are amplified in around 20% of cases (Kauraniemi, Barlund, Monni, & Kallioniemi, 2001; Kauraniemi, Kuukasjarvi, Sauter, & Kallioniemi, 2003). In contrast, inactivating mutants of CDK12 have been found in ovarian cancer and cells expressing a defective CDK12 have functional defects in homologous repair, which makes them sensitive to PARP inhibition (P. M. Joshi, Sutor, Huntoon, & Karnitz, 2014). Genetic siRNA silencing screens have identified CDK12 as a modifier of breast cancer cell sensitivity to tamoxifen through MAPK activation and have also found CDK12 as a determinant of sensitivity to inhibitors of the poly (ADP-ribose) polymerases PARP1 and PARP2 (Bajrami, et al., 2014; Iorns, Martens-de Kemp, Lord, & Ashworth, 2009).

3.4. CDK8/19

As outlined in section 3.1, the unphosphorylated RNA polymerase II assembles at core promoters, where it interacts with the Mediator complex: a highly conserved transcriptional coactivator. The Mediator complex is a large, multisubunit protein complex central to the regulation of transcription in eukaryotes (Allen & Taatjes, 2015; Poss, Ebmeier, & Taatjes, 2013; Yin & Wang, 2014). Acting as a molecular bridge, the Mediator transfers signals from DNA-bound transcription factors to the RNA polymerase II pre-initiation complex. It has a role in recruiting proteins required for transcription elongation (including pTEFb) and transcriptional pausing, and influences chromatin structure, facilitating the formation of enhancer-promoter gene loops (Allen & Taatjes, 2015; Donner, Ebmeier, Taatjes, & Espinosa, 2010; Poss, et al., 2013; Takahashi, et al., 2011; Yin & Wang, 2014).

A four-subunit kinase module containing CDK8, cyclin C and the Mediator subunits MED12 and MED13 also transiently associates with the Mediator complex to regulate transcription (Y. Liu, Ranish, Aebersold, & Hahn, 2001; Taatjes, Naar, Andel, Nogales, & Tjian, 2002). Evidence indicates that the binding of Mediator to the kinase module and to

RNA Pol II is mutually exclusive (Tsai, et al., 2013), suggesting that the interaction between Mediator and the kinase module may be a key checkpoint in the control of transcription. CDK8 knockdown studies have demonstrated reduced CTD phosphorylation at Ser2 and Ser5, impairment of transcriptional elongation and reduced recruitment of super elongation factors to immediate/early-response genes activated in response to serum stimulation (Donner, et al., 2010). Separate work has shown that the HIF1alpha transactivation of gene expression requires the CDK8 module for the recruitment of super elongation factors and their binding to RNA polymerase II, to stimulate the transition from a paused complex to transcriptional elongation (Galbraith, et al., 2013) (**Figure 4**)

As a kinase that reversibly associates with Mediator, CDK8 can regulate gene expression through the phosphorylation of transcription factors. Phosphorylation by CDK8 can directly alter transcription factor activity (Bancerek, et al., 2013; Morris, et al., 2008; J. Zhao, Ramos, & Demma, 2013) or mark factors for degradation (Alarcon, et al., 2009; Fryer, White, & Jones, 2004; X. Zhao, et al., 2012). The CDK8-Mediator complex has been shown to assemble on p53 target genes, including $p21^{CIP1}$, after the exposure of cancer cells to DNA-damaging agents such as radiation therapy, doxycycline and fluorouracil (Donner, et al., 2010). CDK8 phosphorylates STAT1 at Ser727, activating STAT1-regulated transcription in response to IFN-gamma stimulation (Bancerek, et al., 2013). This regulatory pathway is typically associated with antiviral defense and tumor-suppressor functions. However, other evidence has also implicated the STAT1 pathway in cellular resistance to DNA-damage and aggressive tumor growth (Duarte, et al., 2012; Khodarev, et al., 2004; Khodarev, Roizman, & Weichselbaum, 2012). The phosphorylation of STAT1 at Ser727 by CDK8 was found to suppress natural killer cells and the expression of a dominant-negative CDK8 was shown to be more cytotoxic to cancer cells than healthy cells (Putz, et al., 2013).

Other transcriptional activator proteins phosphorylated by CDK8 include the SMAD proteins and NOTCH1. CDK8 phosphorylates an interdomain linker region within the SMAD proteins, which results in their transcriptional activation and primes them for ubiquitin-mediated degradation (Alarcon, et al., 2009). The NOTCH1 protein is a transmembrane receptor that undergoes cleavage when activated to release its intracellular domain, ICN1, which then translocates to the nucleus to activate gene-specific transcription. CDK8 regulates ICN1 activity by phosphorylation, resulting in increased ICN1 ubiquitination and proteasome-driven degradation (Fryer, et al., 2004). CDK8/cyclin C has also been shown to be a negative regulator of the lipogenic pathway, through its phosphorylation of nuclear SREBP-1c at a conserved threonine residue that enhances SREBP-1c ubiquitination and protein degradation (X. Zhao, et al., 2012). Although, much is known about the role of CDK8 in regulating transcription through the repression and activation of transcription factors, CDK8 may also regulate transcription at the chromatin level. CDK8 phosphorylates histone H3 at Ser10 (Knuesel, Meyer, Donner, Espinosa, & Taatjes, 2009), a mark associated with the transcriptional activation of immediate/early-response genes (Strelkov & Davie, 2002). CDK8 also interacts with GCN5L to generate a dual Ser10/Lys14A mark on histone H3 (Meyer, et al., 2008).

Our understanding of the role of CDK8, and the Mediator kinase module, in the control of transcription is complicated by the fact that vertebrates express paralogues of CDK8, MED12 and MED13 (CDK19, MED12L and MED13L respectively). Despite a high degree of sequence similarity, CDK8 and CDK19 can interact with different partners *in vitro* (Tsutsui, et al., 2008) and seem to perform some distinct roles *in vivo* (Galbraith, et al., 2013), which may explain why Cdk19 fails to compensate for the embryonic lethality of the Cdk8 knockout in mice (Westerling, Kuuluvainen, & Makela, 2007). In contrast, conditional Cdk8 knockout in adult mice has no major effects on the homeostasis of normal tissue (McCleland, et al., 2015).

The biological function of CDK8 varies by cell type and in response to different stimuli (Allen & Taatjes, 2015). This is particularly true in the development of cancer, where evidence suggests CDK8 can function as both an oncogene and tumor-suppressor depending on the context. Consistent with a role as a tumor-suppressor, *CDK8* expression is reduced in a subset of bladder cancers (Mitra, et al., 2006) and deletion of the *CDK8* gene is frequently observed in oesophageal squamous cell carcinomas (Chattopadhyay, et al., 2010). In endometrial cells the ectopic expression of *CDK8* blocked xenograft tumor growth and inhibited cell proliferation, migration and invasion; whereas CDK8 knockdown had the opposite effect (Gu, et al., 2013). Similarly, deletion of *Cdk8* in an Apc^{Min} murine tumor model led to an increase in tumor growth rate and size (McCleland, et al., 2015).

In contrast, it has been reported that *CDK8* may function as an oncogene, particularly in the development of colorectal cancer. *CDK8* is frequently amplified in colorectal cancer with copy number gains in ~60% of tumors (Firestein, et al., 2010; Seo, Han, & Lim, 2010), while CDK8 knockdown reportedly reduces the growth of human colorectal cancer tumor xenografts harboring *CDK8* gene amplification (Adler, et al., 2012; Firestein, et al., 2008). Furthermore, studies have indicated that *CDK8* expression is required to maintain colorectal cancer xenografts and embryonic stem cells in an undifferentiated state (Adler, et al., 2012). Importantly, NIH3T3 cells overexpressing wild-type *CDK8* have a malignant phenotype, but those overexpressing a kinase-dead *CDK8* mutant do not (Firestein, et al., 2008). More recently, both CDK8 and CDK19 have been identified as potential therapeutic targets in advanced prostate cancer, where siRNA knockdown or small molecule inhibition decreased invasion and migration (Bragelmann, et al., 2016).

One way in which CDK8 and the Mediator kinase module may promote oncogenesis is through activation of the canonical WNT signaling pathway. The WNT signaling pathway

is critical to metazoan development and misregulation of this pathway has been implicated in a variety of cancers. *CDK8* expression correlates with the activation of β-catenin, a core transcriptional regulator of canonical WNT signaling, in gastric and colon cancers (Firestein, et al., 2010; M. Y. Kim, Han, & Lim, 2011) and shRNA screens have identified a requirement for CDK8 for the activation of WNT-signaling in colorectal cancer cell lines (Firestein, et al., 2008). While MED12 and MED13 stimulate WNT-signaling via a direct interaction between β-catenin and MED12 (Carrera, Janody, Leeds, Duveau, & Treisman, 2008; S. Kim, Xu, Hecht, & Boyer, 2006; Rocha, Scholze, Bleiss, & Schrewe, 2010), CDK8 acts by phosphorylating E2F1, preventing it from promoting the degradation of β-catenin (Morris, et al., 2008; J. Zhao, et al., 2013). Therefore the Mediator kinase module has the ability to drive cancer cell progression by both facilitating the transcription of β-catenin target genes and repressing an opposing degradation pathway.

As outlined in this section, the Mediator-associated kinases CDK8 and CDK19 have been proposed as context-dependent drivers or suppressors of tumorigenesis. Given the role of these proteins in regulation of signal-dependent gene expression and, in particular, their effect on the super-enhancers that regulate gene expression controlling cell identity and disease, inhibiting CDK8/19 would be predicted to have pleiotropic lineage-dependent effects. However, the impact of this on the clinical utility of CDK8/19 inhibitors is unclear, particularly in regard to the size of the therapeutic window between cancerous and healthy tissue.

4. Additional CDKs with a role in cancer

The main focus of this review is the CDKs for which inhibitors have been reported. However, other members of the CDK family may have a role in cancer and in some cases may represent future targets for therapeutic intervention.

4.1. CDK10

CDK10 binds the N-terminal domain of the ETS2 transcription factor and suppresses the ETS2 transactivation domain (Bagella, Giacinti, Simone, & Giordano, 2006; Kasten & Giordano, 2001), consistent with CDK10 functioning as a tumor suppressor, inhibiting the oncogenic potential of MAPK signaling. In a screen designed to identify modifiers of tamoxifen sensitivity in breast cancer, siRNA knockdown of *CDK10* mRNA relieved ETS2 repression, resulting in ETS2-mediated expression of *c-RAF* and increased MAPK-signaling (Iorns, et al., 2008). The result of this MAPK-activation was circumvention of ERα signaling in the tumor cells and continued proliferation in the presence of the anti-estrogen tamoxifen. Correspondingly, the same study provided evidence that breast cancer patients with ERα-positive tumors expressing *CDK10* at low levels are more likely to relapse. Recent studies have identified cyclin L2 as the regulatory cyclin for CDK10, and silencing of *CCNL2* phenocopies *CDK10* silencing, leading to an increase in the level of c-RAF and conferring tamoxifen resistance. CDK10/cyclin L2 was found to phosphorylate ETS2 and induce its degradation by the proteasome (Guen, et al., 2013).

4.2. CDK11

Unlike the other CDK family members, human CDK11 is encoded by highly homologous genes, *CDK11A* and *CDK11B*, unlike mice, which has a single gene (Zhou, Shen, Hornicek, Kan, & Duan, 2016). CDK11 has conserved cyclin-binding domains, a C-terminal catalytic domain and three regulatory phosphorylation sites. In addition, there is an N-terminal regulatory region containing multiple nuclear localization signals, a 14-3-3 consensus binding site, an arginine/glutamic acid domain thought to associate with RNA processing factors, and a poly-glutamic acid domain, which is a potential cytoskeleton-interacting domain. CDK11 binds L-type cyclins and has multiple roles in coordinating

transcription and splicing, developmental signaling, cell cycle regulation, neuronal function, autophagy and apoptosis (Loyer, et al., 2008; Zhou, et al., 2016). Multiple approaches have been taken to identify CDK11-interacting proteins. Aside from the L cyclins, these studies have identified splicing factors, and multiple transcriptional initiation and elongation factors (Hu, Mayeda, Trembley, Lahti, & Kidd, 2003; Loyer, et al., 2008; Loyer, Trembley, Lahti, & Kidd, 1998; Trembley, et al., 2002).

Different isoforms and splice variants of CDK11 have been identified, namely CDK11p46, CDK11p58 and CDK11p110. The larger CDK11p110 kinase is expressed throughout the cell cycle and is a nuclear protein that mainly associates with the transcriptional and splicing apparatus (Hu, et al., 2003; Trembley, et al., 2002; Trembley, et al., 2004). CDK11p58 is produced during M phase and in HeLa cells inhibition of *CDK11* expression using siRNA leads to abnormal spindle assembly, mitotic arrest and cell death (Franck, et al., 2011; Petretti, et al., 2006; Rakkaa, Escude, Giet, Magnaghi-Jaulin, & Jaulin, 2014; Yokoyama, et al., 2008). The CDK11p46 isoform is associated with apoptosis and is generated in response to apoptotic signaling by caspase 1 or 3 activity (Beyaert, et al., 1997). In contrast to the other CDK11 isoforms, CDK11p46 localizes predominantly to the cytoplasm when ectopically expressed. Several non-cyclin partners have been proposed to interact with CDK11p46, including the eukaryotic initiation factor EIF3E and the Ran-binding protein RanBP9 (Mikolajczyk, Shi, Vaillancourt, Sachs, & Nelson, 2003; Shi, et al., 2003).

CDK11 is highly expressed in triple negative breast cancers and is associated with both an advanced stage of disease and a poor clinical prognosis (Zhou, et al., 2015). Silencing of *CDK11* expression significantly inhibits migration, inhibits proliferation and induces apoptosis in breast cancer cell lines (Kren, et al., 2015). Similar results have been observed in multiple myeloma cells where two screens have independently identified *CDK11*A/*B* as crucial survival genes and their proteins as potential targets for therapeutics

(Tiedemann, et al., 2012; Tiedemann, et al., 2010). Furthermore *CDK11* expression has been shown to be increased in primary multiple myeloma samples compared to normal primary tissues. Elevated *CDK11* expression, associated with a poor clinical outcome is observed in osteosarcoma cells and patient biopsies (Zhou, et al., 2016). Moreover, as described for breast cancer and multiple myeloma cells, shRNA and CRISPR/Cas9 genetic knockouts of *CDK11* in osteosarcoma cancer cells significantly reduced cell viability, proliferation, migration, and invasion, and induced cell death (Duan, et al., 2012; Feng, et al., 2015). *CDK11* is also highly expressed in liposarcoma tissues compared with expression in benign lipoma tissues - another type of malignancy that originates in mesenchymal tissue. SiRNA or shRNA inhibition of *CDK11* expression has been found to reduce cell proliferation and induce apoptosis in liposarcoma cells, in addition to enhancing the cytotoxic effect of doxorubicin (Jia, et al., 2014). Overall, *CDK11* is highly expressed in several types of human malignancies and is associated with a poor outcome. Consequently, CDK11 has potential as target for cancer therapy.

4.3. The cyclin Y binding CDKS

CDK14-18 bind cyclin Y, a membrane-associated cyclin whose cellular role remains elusive (Malumbres, 2014)(**Figure 1**). CDK14 participates in the regulation of WNT signaling. The WNT ligands are a family of secreted or cell surface glycoproteins that regulate cell proliferation, survival, migration, polarity, cell fate specification, and stem cell renewal (Clevers & Nusse, 2012). There are multiple seven-pass transmembrane proteins and two single-pass transmembrane low-density receptor-related lipoproteins (LRP5 and LRP6) capable of binding WNT in a ternary complex with Frizzled. LRP6 activation is a key regulatory node for WNT signaling and recent studies have identified multiple signals that can influence LRP6 activation, including inputs from the cell cycle (G. Davidson, et al., 2009). The cell cycle-dependent activation of LRP6 is mediated by the CDK14/cyclin Y complex, which phosphorylates LRP6 at the plasma membrane during

G2/M. Phosphorylation increases the receptiveness of cells to incoming WNT signals and the peak of LRFP6 phosphorylation at G2/M appears to provide a clear mechanistic explanation for the increased activity of WNT signaling reported at G2/M. Cell cycle activation of LRP6 could be a regulatory mechanism to enhance signaling in particular proliferative regions, for example during development or in stem cells.

WNT signaling is closely linked to cancer progression: non-canonical WNT signaling is frequently increased in human hepatocellular carcinoma and CDK14 expression confers increased motility and metastatic potential in this setting (J. Huang, et al., 2012; Leung, et al., 2011; Sun, Co, & Wong, 2014). Recent studies show that CDK14 is highly expressed in several malignant tumors such as hepatocellular carcinoma, esophageal cancer, breast cancer, and gastric cancer, with roles in the regulation of the cell cycle, tumor proliferation, migration, and invasion (L. Yang, et al., 2015). Although there are many questions still to be answered regarding the role of CDK14 in WNT signaling, these links suggest that targeting CDK14 has therapeutic potential in the treatment of cancer.

Of the remaining cyclin Y binding CDKs, CDK15 has been found in a hepatitis B virus-gene fusion in hepatocellular carcinomas and may participate in hepatitis B virus driven transformation (Shiraishi, et al., 2014). CDK16 acts via mechanisms unknown to regulate p27Kip1 stability, mitosis, apoptosis, and growth in multiple cancer cell lines (prostate, breast, cervical cancers, and melanomas). Hence the inhibition of CDK16 may provide a strategy for the treatment of some human cancers with pathological elevations in the activity of this kinase (Yanagi & Matsuzawa, 2015).

4.4 CDKs with poorly defined functions

There remain classes of CDKs for which the underlying functions are unclear. CDK3 was found to be intrinsically important for cell cycle control based on cell-based experiments

that used a dominant-negative version of CDK3 (van den Heuvel & Harlow, 1993). However, there are mouse strains that harbour an inactive CDK3 suggesting that its role in the cell cycle can be readily compensated for (Ye, Zhu, & Harper, 2001). CDK5 was largely viewed as a neuronal kinase; however, recent work suggests that it has functions similar to CDK4 and CDK2 in driving progression from G1–S and in RB phosphorylation in medullary thyroid cancer models and as such may be a therapeutic target at least in this cancer type (Pozo, et al., 2013). Finally, CDK20 interacts with cyclin H and was thought to phosphorylate and activate CDK2, suggesting a close relationship with CDK7; however, this suggestion remains controversial. Recent data suggest that CDK20 activates ICK or β-catenin-TCF signaling to stimulate cell-cycle progression (Malumbres, 2014).

5. Small molecule CDK inhibitors

The majority of protein kinase inhibitors developed to date are type I inhibitors: they bind at the ATP–binding site, are ATP-competitive and target the kinase in its active state, with the activation loop DFG motif in the 'in' position. In contrast, type II inhibitors can bind kinases that are in an inactive conformation, with the DFG motif flipped 'out'. In addition to binding the ATP binding site, Type II inhibitors can also occupy a hydrophobic site, made accessible by the flipped "out" conformation of the DFG motif. Type II inhibitors are believed to be more selective than Type I inhibitors, however for both type of compounds there are examples of both highly selective and non-selective inhibitors (Treiber & Shah, 2013). The development of selective CDK/cyclin inhibitors was initially thought to be challenging since it was commonly believed that cyclin binding prevented the conformational change required at the ATP-binding site to generate a type II inhibitor-binding pocket, thus restricting the inhibitors to type I binding modes. In addition, the high degree of similarity between the ATP-binding sites of the CDKs was also predicted to be a challenge to generating isoform-selective inhibitors. Consistent with this the early type I inhibitors were generally found to be promiscuous across multiple CDKs. However, as

described in this review it is now clear that it is possible to identify and develop potent CDK-selective type I inhibitors and also inhibitors that bind with a type II mode.

The first CDK inhibitors were developed predominantly against CDK2 and were relatively unselective, but acted as early pathfinder agents. These inhibitors encompassed heteroaromatic scaffolds including flavonoid, purine, indenopyrazole, aminopyrimidine, aminothiazole, indirubin, hymenialdisine, and paullone derivatives (Asghar, et al., 2015; Sanchez-Martinez, Gelbert, Lallena, & de Dios, 2015). Below we describe the early pan-CDK inhibitors and the improvements that have led to the current clinical studies with multi-target CDK inhibitors. We also discuss recent exciting advances in the development of isoform-selective CDK inhibitors.

5.1. Early pan-CDK inhibitors

Among the first CDK inhibitors to advance to clinical trial were alvocidib (flavopiridol; **1**) and seliciclib (roscovitine/CYC202; **2**) (**Figure 5**). These are pan-CDK inhibitors: alvocidib inhibits CDKs 1, 2, 4, 6, 7 and 9 and seliciclib inhibits CDKs 1, 2, 5, 7 and 9. These agents produce G1 and G2 phase cell cycle arrest and apoptosis, an effect initially attributed to their inhibition of the cell cycle CDKs (Carlson, Dubay, Sausville, Brizuela, & Worland, 1996; Meijer, et al., 1997). However, later work indicated that many of the cellular activities of these inhibitors were probably the result of CDK7 or CDK9 inhibition including the transcriptional inhibition of cell cycle and apoptosis-related genes (L. T. Lam, et al., 2001; MacCallum, et al., 2005; Whittaker, et al., 2007; Whittaker, Walton, Garrett, & Workman, 2004). Alvocidib has demonstrated some clinical efficacy in hematological malignancies such as chronic lymphocytic leukemia (CLL), but responses were limited by toxicity (Aklilu, Kindler, Donehower, Mani, & Vokes, 2003; Burdette-Radoux, et al., 2004; Byrd, et al., 2007; Byrd, et al., 2005; G. Liu, et al., 2004; Schwartz, et al., 2001). Seliciclib was examined in two Phase I studies (Benson, et al., 2007; Le Tourneau, et al., 2010).

The peak plasma levels of Seliciclib were not sufficiently sustained for antiproliferative effects, as modeled *in vitro* (Raynaud, et al., 2005). Consistent with this, attempts to measure RB phosphorylation and cyclin D1 expression biomarkers did not reliably show modulation on treatment (Benson, et al., 2007). While no objective responses were observed, disease stabilization was observed, with one ovarian cancer patient remaining on therapy for 18 weeks.

The side-effects associated with these early pan-CDK inhibitors include nausea, vomiting, fatigue and hepatic dysfunction, with alvocidib also causing myelosuppression. Alternative dosing schedules were identified that permitted slightly higher, but intermittent, dosing frequencies (Le Tourneau, et al., 2010), and seliciclib has now been evaluated in 16 clinical trials, including combination studies. Ongoing studies are investigating activity in *BRCA* mutant tumors in combination with sapacitabine, a nucleoside analogue (Tolaney, et al., 2016; W. Yeo, 2009). Notably, this combination resulted in a disease control rate of 35.6%; mainly stable disease, in heavily pretreated patients with tumors of breast, ovarian and pancreatic origin. Mechanistically, suppression of BRCA protein expression and CDK2 and CDK9 activities by seliciclib is implicated in the potentiation of DNA damage induced by sapacitabine.

While data from mouse models has led some to question the requirement for specific CDKs to mediate cell cycle progression (see section 2), evidence suggests that CDK1 may be an essential cell cycle CDK (Santamaria, et al., 2007). However, because the biological consequences of knocking out a gene target and inhibiting protein activity with a drug can be phenotypically different, the development of more selective CDK inhibitors may help to delineate the mechanisms of therapeutic response and the cause of pan-CDK inhibitor toxicity.

5.2. Multitarget CDK inhibitors

Dinaciclib (**3; Figure 5**) is a near-equipotent inhibitor of CDK1, CDK2, CDK5 and CDK9, which blocks DNA replication in ovarian carcinoma cells with low single digit nM IC_{50}s. The compound displays good selectivity for CDKs over other kinases and is active in a broad range of cancer cell lines originating from multiple tumor types. Importantly, measurement of inhibition of RB phosphorylation in response to dinaciclib application has confirmed target engagement in cells, with apoptosis induced at between 12 and 500 nM. Interestingly, only 2 h transient exposures to dinaciclib are required to bring about these molecular changes, which are sustained for 6 h in the absence of the drug. Dinaciclib has shown good efficacy *in vivo* and is well tolerated, with daily intraperitoneal dosing inhibiting ovarian xenograft growth over 10 days. In terms of haematological effects, dinaciclib treatment has been shown to reversibly depress neutrophil and reticulocyte counts (Parry, et al., 2010). Dinaciclib has shown some activity in *MYCN*-driven neuroblastoma, attributed to inhibition of CDK2 and CDK9 (Z. Chen, et al., 2016). The overexpression of CDK2 in neuroblastoma tissue is associated with poor overall survival, suggesting a potential strategy for patient selection during clinical development of this drug (Z. Chen, et al., 2016).

Phase I testing of dinaciclib was conducted in 48 patients with advanced solid tumors receiving a 2 h infusion once a week for 3 weeks. Dose-limiting toxicities (DLTs) reported included orthostatic hypotension and elevated uric acid; however, overall, the drug was well tolerated, with stable disease observed in 10 patients (Nemunaitis, et al., 2013). Dinaciclib progressed into Phase II trials in patients with breast cancer and non-small cell lung cancer; however, in both studies time to disease progression was shorter with dinaciclib than the standard-of-care, and the trials were terminated early (Mita, et al., 2014). Given the promising results observed with the first generation CDK inhibitor alvocidib in relapsed and refractory CLL (Byrd, et al., 2007), the clinical activity of dinaciclib was also studied in this population (Flynn, et al., 2015). Strikingly, 54%

responded to treatment with dinaciclib, with cytopenia and tumor lysis syndrome reported as associated adverse events. A followup Phase III trial of dinaciclib versus ofatumumab (an antibody targeting the CD20 antigen) in refractory CLL was terminated early, but did demonstrate activity (Ghia, et al., 2015). Additional studies of the activity of dinaciclib against other hematological cancers, such as multiple myeloma, have shown a response rate of 11% (Kumar, et al., 2015). Ongoing studies are looking at the efficacy of dinaciclib treatment in combination with immunotherapy (pembrolizumab) or PARP inhibition (veliparib) (Hossain, et al., 2016).

AT7519 (**4; Figure 5**) was discovered through a structure-guided, fragment-based, screen (Wyatt, et al., 2008). The compound inhibits CDK1, 2, 4, 5, 6 and 9. Cellular activity across a broad panel of human cancer cell lines has been observed, with GI_{50} values ranging from 40 to 940 nM. Evidence that inhibition of CDK4/6 were dispensable for activity came from observations that cell lines lacking functional RB retain sensitivity to AT7519 and the modulation of the CDK4/6 phosphorylation site Ser780 on RB was not affected by treatment (Squires, et al., 2009). Inhibition of NPM1 and other RB phosphorylation sites as early as 1 h post-treatment is consistent with the AT7519 having a direct effect on CDK2 activity; while the inhibition of PP1A phosphorylation was only reported at 24 h, suggesting that the effect of AT7519 on CDK1 activity in cells may be modest. Finally, treatment with AT7519 inhibits the phosphorylation of RNA polymerase II CTD Ser2 and blocks global transcription with an IC_{50} of 56 nM, reflective of an inhibition of CDK9 activity (Squires, et al., 2009).

AT7519 treatment causes cell cycle arrest at G0/G1 and G2/M. The compound has excellent antitumor efficacy in human colorectal cancer xenograft models, with extensive tumor regression, the modulation of pharmacodynamic biomarkers and elevated PARP cleavage indicating apoptotic cell death (Squires, et al., 2009). A Phase I trial of AT7519 in refractory solid tumors showed evidence of activity with 4 out of 28 patients

experiencing stable disease and one a prolonged partial response, but had to be discontinued because of DLT, particularly an increase in cardiac QTc (Mahadevan, et al., 2011). A second Phase I study in advanced refractory solid tumors and non-Hodgkin's lymphoma did not report significant cardiac QTc prolongation and 10 of 19 patients had stable disease (E. X. Chen, et al., 2014).

Hematological cancers appear particularly susceptible to AT7519 treatment. These cancers are known to depend upon transcripts with short half-lives, such as *MCL1*, *BCL2* and *XIAP*, and AT7519 has been shown to inhibit *MCL1* expression in an HL60 xenograft model in which it induced tumor regression. Patient-derived CLL cells have also been shown to respond to a brief exposure to AT7519, undergoing apoptosis at concentrations of drug that can be safely achieved in patients for >12 h (Squires, et al., 2010). Further clinical investigation of AT7519 is underway in multiple myeloma, mantle cell lymphoma and chronic lymphocytic leukemia.

Recently, a role for AT7519 has also been described in the treatment of neuroblastoma. *MYCN*-amplified neuroblastoma cell lines were shown to be more prone to AT7519-induced apoptosis than non-amplified lines, despite similar levels of RB phosphorylation (Dolman, et al., 2015). Furthermore, AT7519 has shown activity in a *MYCN*-amplified AMC711T neuroblastoma xenograft model with 3 weeks treatment giving near complete inhibition of tumor growth and suppression of NPM and RB phosphorylation. AT7519 also suppressed the growth of tumors in Th-*MYCN* transgenic mice; the treated mice showed partial responses and survived significantly longer than the controls (Dolman, et al., 2015). Notably, this study did not resolve the contribution of specific CDKs to the activity observed in neuroblastoma, showing CDK2 substrates were clearly inhibited, but not assessing any CDK9-dependent effects.

CYC065 is a second generation CDK inhibitor optimised from seliciclib and CCT068127 (Wilson, et al., 2011). The compound shows greatest potency against CDKs 2, 5 and 9 (Frame, Saladino, Davis, Blake, & Zheleva, 2014). CYC065 has been tested in preclinical models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia and is thought to restrict the proliferation and survival of leukemia cell lines by inhibiting CDK9, which reduces RNA polymerase II-mediated transcription and *MCL1* expression, inducing apoptosis. Furthermore, CYC065 can suppress *MEIS1* expression, a transcriptional cofactor, which is required for the induction and maintenance of mixed-lineage leukemic stem cells via promotion of cell cycle progression and inhibition of differentiation (Wong, Iwasaki, Somervaille, So, & Cleary, 2007). Oral dosing of mice with CYC065 led to a >90% reduction in the growth of EOL-1 and HL60 AML xenografts (Frame, et al., 2014). CYC065 and the related compound CCT068127 both inhibit *MCL1* expression, it has been suggested that co-treatment with BCL2 family inhibitors may be synergistic and drive cells into apoptosis (Frame, et al., 2014)(Whittaker *et al*, submitted). Consistent with this hypothesis, the effect of ABT-263 and CYC065 or CCT068127 on AML, acute lymphoblastic leukemia and colorectal cancer cell lines suggests that these inhibitors have synergistic activity (Frame, et al., 2014) (Whittaker *et al*, submitted).

CYC065-mediated CDK2 inhibition may have a role in solid tumors, for example in trastuzumab-refractory, HER2+ breast cancer, as treatment with CYC065 has been shown to induce apoptosis and suppress tumor growth in these xenograft models perhaps through a dependence on CCNE1 (Scaltriti, et al., 2011). *CCNE1* amplification is also a feature of uterine serous carcinoma and confers sensitivity to CYC065 in cell line models. *PIK3CA* mutation and/or amplification is also a common event in uterine serous carcinomas and treatment with CYC065 and GDC-0032, a selective class I PI3K inhibitor, has shown synergy *in vitro* and greater efficacy than monotherapy *in vivo* (Cocco, et al., 2016). While the activity of CYC065 was attributed to its inhibition of CDK2 in these latter two examples, the potential for CYC065 to inhibit CDK9, and hence decrease the

transcription of genes involved in cell proliferation and survival, was not assessed. Transcriptional inhibition by CYC065 may be effective in neuroblastoma, as in leukemia, and warrant clinical investigation. Depletion of MYCN, a key driver of neuroblastoma, has been observed in human cancer cell lines, human tumor xenograft and mouse models treated with CYC065; similarly, CYC065 inhibited neuroblastoma cell proliferation and induced apoptosis, prolonging the survival of treated mice (Poon, et al., 2016). CYC065 has now entered a Phase I dose-escalation clinical trial in patients with advanced cancers.

Several other multitarget CDK inhibitors have failed or not progressed beyond early clinical studies for example RGB-286638, ZK-304709, and P1446A-05 (**5**-**7; Figure 5)** were discontinued during phase I or phase II trials (Asghar, et al., 2015; Sanchez-Martinez, et al., 2015). P276-00 (**8**; **Figure 5**) ceased clinical studies following a commercial decision by the sponsor company (K. S. Joshi, et al., 2007). R547 (**9**; **Figure 5**) is an inhibitor of CDKs 1, 2 and 4, with reduced potency for CDK7, GSK3a and GSK3b, and was tested in a Phase I trial in 2007, but has not been progressed further despite reports of manageable toxicity (Diab, et al., 2007). SNS-032/BMS-387032 (**10**; **Figure 5**) was originally thought to be selective for CDK2 over CDKs 1 and 4, but is now known to also target CDK7 and CDK9. This compound was tested in two Phase I clinical studies, but these have not been followed up (Heath, Bible, Martell, Adelman, & Lorusso, 2008; Tong, et al., 2010). AZD5438 (**11**; **Figure 5**) is an inhibitor with selectivity for CDKs 1, 2 and 9 over CDKs 5 and 6, and was not tolerated in Phase I trials, halting the clinical development of this compound (Boss, et al., 2010; Byth, et al., 2009). Finally, AG-024322 (**12**; **Figure 5**), an inhibitor of CDKs 1, 2 and 4 failed in its initial Phase I study (Asghar, et al., 2015).

There are a number of other agents that display multi-targeted activity, including the inhibition of CDKs that are undergoing clinical investigation. PHA-848125 (milciclib, **13; Figure 4)** is a dual tropomyosin receptor kinase A and CDK2 inhibitor, with 4 to 10-fold

selectivity versus other CDKs and receptor tyrosine kinases (Albanese, et al., 2010; Brasca, et al., 2009). Given the multitargeted nature of the compound, broad-spectrum antitumor activity was observed across a ~200 cell line panel. The compound was assessed in a Phase I trial with 2 of 37 patients experiencing a partial responses, whom both had thymic carcinomas, a disease associated with loss of CIP/KIP family proteins and possibly TRK activation (Weiss, et al., 2012) and a Phase II investigation in thymic carcinoma patients is ongoing. BAY-1000394 (roniciclib, **14; Figure 4**) is a low nM inhibitor of CDKs 1-5, 7, and 9 and shows sub-100 nM activity against 16 other kinases (Siemeister, et al., 2012). Broad activity in human cancer cell line panels was observed, with no cell line exhibiting a GI_{50} of more than 100 nM. (Siemeister, et al., 2012). Clinical investigation in solid tumor populations showed signs of activity (10 of 25 patients had stable disease) with acceptable tolerability (Bahleda, et al., 2012). TG02 (**15; Figure 4)** is the most advanced compound to emerge from optimization of a macrocyclic structure (William, et al., 2012), and is a low nM inhibitor of CDK1, 2, 3, 5, 7 and 9 that inhibits a broad range of other kinases, including FLT3 and JAK2 and members of the SRC family (Goh, et al., 2012). As observed above, such multitargeted behavior also translates to broad antiproliferative activity in cell line panels and this is also true for TG02. Results of the Phase I trials of this compound are yet to be reported.

Overall, the clearest indication of clinical activity of CDK1/2/9 inhibitors has been in hematological malignancies. Preclinical data also supports the case for further clinical investigation into the effectiveness of CDK1/2/9 inhibitors in *MYCN*-driven or *CDK2* over-expressing neuroblastoma. Rational patient selection strategies should help to elucidate the critical targets of these multitarget inhibitors and inform attempts to define how best to further deploy these agents in the clinic.

5.3 Selective CDK inhibitors

5.3.1 CDK4/6

Palbociclib (PD0332991) (**16**; **Figure 6**) was reported in 2004 as a specific, low nM inhibitor of CDKs 4 and 6 and no appreciable activity against 36 additional kinases. It was shown to potently inhibit RB phosphorylation at Ser780, with an IC_{50} value of 63 nM in MDA-MB-435 cells (Rae, Creighton, Meck, Haddad, & Johnson, 2007) and inhibit the proliferation of human breast, colon, lung and leukemia cell lines, with GI_{50} values ranging from 40 to 170 nM. Consistent with its kinase selectivity profile, palbociclib shows no antiproliferative activity in *RB*-deleted cell lines where the requirement for CDK4/6 is bypassed. As expected for a compound that inhibits CDK4/6 activity, palbociclib treatment led to a profound G1 arrest and cytostasis, which raised concerns about the ability of this approach to successfully induce tumor regression. However, notably in mice bearing human breast and colorectal xenografts oral treatment with palbociclib induced tumor regressions, with confirmed inhibition of RB phosphorylation in tumor lysates (Fry, et al., 2004). Subsequent studies of palbociclib focused on hematological cancers such as multiple myeloma and mantle cell lymphoma, in which cyclin D-dependent CDKs are deregulated (Baughn, et al., 2006; Marzec, et al., 2006). The most important advance came in 2009, where palbociclib was shown to display activity in luminal ER+ and *HER2* amplified breast cancer cell lines, including those with high levels of cyclin D1 and RB, and low levels of the CDK-regulator CDKN2A (R. S. Finn, et al., 2009). Importantly, this work established that the level of estrogen-induced cyclin D expression could be used to identify patients that may benefit from CDK4/6 inhibition. Correspondingly, the combined inhibition of estrogen-dependent signalling and CDK4/6 activity was shown to be particularly effective, with palbociclib and the antiestrogen tamoxifen showing synergy in breast cancer cell lines and palbociclib treatment able to overcome acquired resistance to tamoxifen (Finn, et al., 2009).

Studies of resistance to palbociclib have indicated that its efficacy can be limited by increased *CDK2* expression/activity and elevated *RBL1* expression (Dean, Thangavel, McClendon, Reed, & Knudsen, 2010). It has recently been disclosed that in response to palbociclib, CDK2 is able to bind cyclin D1 in ER+ breast cancer, mediate RB phosphorylation, promote S phase entry and enable adaptation to palbociclib. Furthermore, in a model of acquired resistance to palbociclib *CCNE1* amplification increased levels of CDK2/CCNE1, leading to sustained RB inactivation and resistance to CDK4/6 inhibition (Herrera-Abreu, et al., 2016). Screening of a drug library in palbociclib-resistant cells uncovered a role for PI3K inhibitors in preventing the emergence of palbociclib-resistant clones; blocking PI3K can suppress cyclin D1 expression, which in concert with CDK4/6 inhibition prevents resistance. Synergy between CDK4 and PI3K inhibitors has also been described in an independent study (Vora, et al., 2014). Finally, CDK4 inhibition has been shown to be a promising therapeutic strategy in preclinical models of RAS-driven melanoma, NSCLC and colorectal cancer (Kwong, et al., 2012; Lee, et al., 2016; Puyol, et al., 2010). These pharmacological studies show how the G1/S checkpoint can be compromised in oncogene-driven cancers to drive resistance, indicating new opportunities for therapeutic intervention.

As with the pre-clinical studies, the clinical development of palbociclib has been protracted. The first Phase I trial in RB+ tumors reported good tolerability with 1 testicular cancer patient achieving a partial response and 9 exhibiting stable disease (Schwartz, et al., 2011). Similar responses were observed in a second Phase I trial where, the only significant toxicity reported was neutropenia (Flaherty, et al., 2012). Pharmacokinetic/pharmacodynamic analysis of these trials assessed absolute neutrophil counts and platelet levels, which were shown to decrease with increasing exposure, consistent with the effects of CDK inhibition in rapidly proliferating cells. Direct target engagement biomarkers such as RB phosphorylation were not reported. Palbociclib was subsequently assessed in a Phase II trial for CDK4-amplified lip sarcoma and was

deemed beneficial (Dickson, et al., 2013). Significantly, in a key Phase II trial of palbociclib (PALOMA-1) carried out in postmenopausal women with HER2-, ER+ breast cancer, the addition of palbociclib to treatment with the anti-estrogen drug letrozole nearly doubled progression free survival (PFS) (R. S. Finn, et al., 2015; Richard S. Finn, et al., 2014). Surprisingly, a second cohort of patients with *CCND1* amplification did not have a better response to the combined treatment than patients selected only on the basis of having ER+/HER2- tumors. This implies that ER status is a primary driver of the palbociclib response, and other lesions in the RB pathway (barring RB loss) do not enhance the therapeutic response and could potentially dampen it. A Phase III trial in patients with ER+/HER2- advanced breast cancer confirmed the Phase II data, with a median PFS of 24.8 months in the palbociclib plus letrozole cohort versus 14.5 months in the letrozole only cohort. The drug was generally well tolerated with grade 3 neutropenia the most common adverse event (R.S. Finn, et al., 2016). Palbociclib was also tested with an alternative hormonal therapy, fulvestrant, in ER+/HER- metastatic breast cancer that had progressed on prior endocrine therapy. Again palbocicilib improved outcome, with a median PFS of 9.5 months in the palbociclib plus fulvestrant group versus 4.6 months in the fulvestrant plus placebo group, with neutropenia again reported to be associated with palbociclib treatment (Cristofanilli, et al., 2016; Harbeck, et al., 2016; Turner, et al., 2015; Verma, et al., 2016). Intrinsic or acquired resistance to endocrine therapy is a near universal feature of ER+ breast cancer, including mutations in the *ESR1* gene (that encodes the ER). These mutations are enriched in patients following aromatase inhibitor therapy, hence it was important understand how this affects the response to palbociclib. Notably, the combination of palbociclib and fulvestrant demonstrated comparable activity in patients with either mutant or wildtype *ESR1* with median PFS of 9.4 versus 9.5 months respectively (Fribbens, et al., 2016). Palbociclib is now approved in combination with letrozole for the treatment of postmenopausal women with ER+/HER2- advanced breast cancer as an initial endocrine therapy and in

combination with fulvestrant in ER+/HER2- patients showing disease progression following endocrine therapy.

Abemaciclib (LY2835219) (**17**; **Figure 6**) is a selective inhibitor of CDK4 and CDK6, with reduced potency against CDKs 1, 2, 7 and 9. Abemaciclib treatment inhibits RB phosphorylation, with IC_{50} values ranging from 60 to 120 nM, and induces a G1 arrest at similar concentrations. Notably, despite being relatively potent against CDK9 *in vitro*, abemaciclib was only able to inhibit the phosphorylation of RNA polymerase II at significantly higher concentrations of 3.5 μM, suggesting it may not be a relevant target in more complex systems. Treatment of mice bearing COLO205 colorectal xenografts with daily abemaciclib inhibited RB phosphorylation, gave maximal inhibition at 24 h post-dosing, and led to a decrease in the abundance of topoisomerase IIa and phospho-histone H3, markers of S and M phases of the cell cycle respectively. Treatment was well tolerated and tumor xenograft growth was significantly inhibited (Gelbert, et al., 2014).

Blocking CDK4/6 activity has been shown to overcome resistance to BRAF inhibition in melanoma, frequently through MAPK pathway reactivation and the expression of cyclin D1. BRAF inhibitor (vemurafenib)-resistant cells are highly sensitised to abemaciclib: treatment with abemaciclib results in a profound induction of apoptosis in vemurafenib-resistant cells, but only G1 arrest in parental cells. This is indicative of a greater dependency on cyclin D-associated CDK4/6 activity in vemurafenib-resistant cells (Yadav, et al., 2014).

Abemaciclib has been investigated in a Phase I dose escalation trial in patients with NSCLC, glioblastoma, breast cancer, melanoma or colorectal cancer. The DLTs were fatigue plus gastrointestinal, renal and hematological events, which occurred early and were reversible. Toxicity was milder than observed with palbociclib or ribociclib and in patients with stable disease or a measurable response; a significant biomarker response

was detected for RB S780 phosphorylation inhibition and topoisomerase IIa abundance in skin biopsies (Patnaik, et al., 2016). The value of pharmacodynamics biomarkers was highlighted when serial monitoring of RB phosphorylation in keratinocytes following dosing enabled selection of a schedule that gave a more sustained pharmcodynamic inhibition between doses. Similar responses were reportedly observed in tumor biopsies. In particular, inhibition of RB phosphorylation by 60% or greater was able to predict for disease control (Patnaik, et al., 2016). The evaluation of abemaciclib in advanced ER+/HER2- breast cancer was performed in an expansion cohort of the Phase I trial, and in these heavily pretreated patients the disease control rate was 72%. Abemaciclib activity was also assessed in pretreated NSCLC patients, including patients bearing tumors with *KRAS* mutations. A disease control rate of 49% was achieved in these patients – 55% in the *KRAS*-mutant patients and 39% in the *KRAS* wildtype patients (Patnaik, et al., 2016). This is in agreement with data from preclinical studies that indicated a synthetic lethal interaction between *CDK4* loss and *KRAS*-mutation in a mouse model of NSCLC (Puyol, et al., 2010). Abemaciclib has shown clinical activity in other tumor-specific cohorts (ovarian cancer, glioblastoma, melanoma and colorectal cancer) and preliminary combination studies with hormonal therapy have reported activity in a small cohort of ER+ metastatic breast cancer patients treated with abemaciclib and fulvestrant, with no discontinuations due to toxicity (Amita Patnaik, 2014). Abemaciclib received breakthrough therapy designation from the FDA in 2015 and 28 clinical trials of this agents are currently underway (www.clinicaltrials.gov). These include combinations with tamoxifen or other targeted agents such as everolimus or trastuzumab, in metastatic breast cancer, *KRAS* mutant non-small cell lung cancer, various advanced cancers including melanoma and colorectal cancer and in dedifferentiated liposarcomas.

Ribociclib (LEE011) (**18**; **Figure 6**) is a selective inhibitor of CDK4/6 that lacks significant activity against CDK1 and CDK2, but, to our knowledge activity against other CDKs has not been reported. Initial work examined the activity of ribociclib in liposarcoma cells,

because of the strong expression of *CDK4* and resulting inactivation of RB. Ribociclib treatment of liposarcoma cells inhibited proliferation, with IC_{50} values ranging from 130 to 240 nM, and produced a robust G0/G1 arrest within 24 h (Y. X. Zhang, et al., 2014). Loss of RB, via siRNA knockdown, reduced the sensitivity of cells to ribociclib. Three doses of ribociclib were sufficient to decrease RB phosphorylation in human liposarcoma, CDK4 amplified LP6 xenografts; while longer continuous treatment with ribociclib significantly reduced tumor growth (Y. X. Zhang, et al., 2014). Human primary liposarcoma xenografts displayed greater sensitivity to ribociclib than secondary tumors, showing near-complete inhibition of tumor growth and durable regressions. Interestingly, chronic exposure to ribociclib was associated with the restoration of RB phosphorylation, likely driven by re-expression of D-type cyclins, although cells retained sensitivity to ribociclib when rechallenged with the compound following a washout protocol (Y. X. Zhang, et al., 2014). Ribociclib has also shown good activity in cellular models of neuroblastoma. *CDK4*, *CDK6* and *CCND1* are all amplified or overexpressed in neuroblastoma cell lines, with significantly greater levels of RB phosphorylation observed in *MYCN* amplified cell lines. Knockdown of CDK4/6 by siRNA achieved greater antiproliferative effects in these *MYCN* amplified cell lines and was phenocopied by ribociclib treatment. The FOXM1 transcription factor has recently been described as a substrate of CDK4/6, where phosphorylation stabilises FOXM1 promoting expression of G1/S phase genes and limiting the accumulation of reactive oxygen species. Ribociclib-treated cells had elevated staining of the senescence marker SA-β-galactosidase, consistent with CDK4/6 inhibition causing a loss of FOXM1 activity. Xenograft models of human neuroblastoma were sensitive to ribociclib, commensurate with a loss of RB phosphorylation (Rader, et al., 2013). A large-scale screen of patient-derived xenografts has boosted optimism about more widespread clinical utility of CDK4/6 inhibition; ribociclib demonstrated synergy in combination with a number of agents (Gao, et al., 2015).

In a Phase I dose escalation trial of ribociclib in 132 patients with RB+ advanced solid tumors or lymphomas 3 patients had a partial response and 43 patients had stable disease (Infante, et al., 2016). DLTs were neutropenia and thrombocytopenia and common adverse events were neutropenia, leukopenia, fatigue and nausea and at higher doses cardiac QT prolongation was also observed. RB phosphorylation was reduced in skin biopsies but levels in tumor biopsies were inconsistent and not dose-dependent, potentially due to the labile nature of phospho-epitopes in tissue samples. Interestingly, *CCND1* amplification was associated with longer treatments, whereas *CDKN2A*/*2B* loss was observed in patients with shorter on-treatment times (Infante, et al., 2016). Ribociclib received FDA breakthrough therapy designation in 2016 and currently there are 42 clinical trials involving ribociclib underway (www.clinicaltrials.gov). Studies include a Phase II trial in patients with advanced liposarcoma, combination studies with letrozole in patients with HR+/HER2- advanced breast cancer and combination studies with BRAF, MEK or PI3K inhibitors.

Overall, the experience gained from the development of CDK4/6 inhibitors described has emphasised the importance of defining pharmacokinetic/pharmacodynamic relationships in early phase clinical trials for optimising dosing schedules and also patient selection biomarkers that can find potential for widening the clinical scope of these agents through combination, extending their use to other cancers. Clinic resistance to therapy is a common feature of all protein kinase inhibitors and strategies to prevent or overcome this will almost certainly be required for CDK4/6 inhibitors as resistant mechanisms are revealed. Early identification of resistance mechanisms or biomarkers is critical and *in vitro* and *in vivo* studies are beginning to elucidate the molecular mechanisms that may drive resistance to this class of inhibitor.

5.3.2. CDK7

A number of compounds have shown promise as selective inhibitors of CDK7. These include LDC3140 (**19**) and LDC4297 (**20**; **Figure 7**), which when applied to tumor cells at low concentrations cause the rapid clearance of paused RNA polymerase II, alter gene expression and induce tumor cell death. At higher concentrations these inhibitors reduce phosphorylation of the RNA polymerase CTD at Ser5 and Ser7 (Kelso, et al., 2014). The recently developed CDK7 inhibitors, THZ1 and THZ2 (**21** and **22**; **Figure 7**), have also proved valuable tool compounds for exploring CDK7 function (Kwiatkowski, et al., 2014). The specificity of these inhibitors derives from their ability to interact with a conserved cysteine residue outside the catalytic domain of CDK7, which is absent in other CDKs. Treatment inhibits the phosphorylation of the RNA polymerase CTD at Ser2, Ser5 and Ser7 and has antitumor activity in multiple tumor types, including aggressive and heterogeneous cancers, such as neuroblastoma, small cell lung cancer and triple-negative breast cancer, with poorly defined oncogenic driver mutations (Chipumuro, et al., 2014; Christensen, et al., 2014; Kwiatkowski, et al., 2014; Y. Wang, et al., 2015). In general, these tumors had an amplification of one of the *MYC* family members, neuroendocrine lineage-specific factors and/or high levels of transcription of genes that promote an oncogenic phenotype. Interestingly, these regions of high transcription have clusters of enhancers, known as super-enhancers, suggesting that the responsiveness of cells to these is due to the sensitivity of super-enhancers to CDK7 inhibition.

THZ1 has also proved a valuable tool to explore the role and requirement for CDK7 during preinitiation. Treatment of nuclear extracts, and eventually cells, with THZ1 revealed the critical role of CDK7 in phosphorylating CTD Ser5 and Ser7 leading to an exchange of general transcription factors and recruitment of DSIF, NELF and the human capping enzyme (HCE) that generates the m^7G cap on the 5' of mRNAs (Nilson, et al., 2015). The m^7G cap is subsequently required for efficient mRNA translation via cap-dependent translation. Inhibition of CDK7 with THZ1 resulted in defective CTD phosphorylation, co-

transcriptional capping, promoter proximal pausing due to a block of DSF and NELF loading and finally the pTEFb-mediated transition into transcriptional elongation.

The findings in antitumor experiments described above were counter to the concern that basic processes such as transcription would make poor targets for therapeutics as they would not select for cancer cells and would have a poor therapeutic window. It is not clear why normal cells are insensitive, or at the very least less sensitive, to CDK7 inhibition. One explanation is that normal cells do not require the high levels of transcription driven by super-enhancers, or that in normal cells phosphorylation of the CTD at Ser5 can be independent of CDK7. In contrast, the tumor cells are dependent on or addicted to CDK7 for their survival. The identification of so-called 'Achilles cluster' of super-enhancer-regulated and CDK7-dependent genes, which are required for cancer cell survival, is consistent with this idea (Y. Wang et al., 2015). Although well tolerated in the mouse xenograft studies one concern is that long-term exposure to CDK7 will deplete pluripotent cells as observed in the CDK7 knockout mice (Ganuza, et al., 2012; Rossi, et al., 2001). This may not be due to the transcriptional effects following CDK7 inhibition, but instead as a result of the CAK activity of CDK7 required to maintain the activity of other CDKs including CDK1, 2 and 9 that may be required by pluripotent cells (Ganuza, et al., 2012; Rossi, et al., 2001). However, potential toxicological effects will only be revealed in dedicated tolerability studies carried out in higher animal species.

5.3.3. CDK9

Recently, CDK9 has emerged as a potential target for cancer therapeutics, as CDK9 regulates the transcription of genes encoding short-lived antiapoptotic proteins, such as MCL1 and XIAP, which are critical for the survival of transformed cells. Attempts to identify selective CDK9 inhibitors by screening focused chemical libraries containing diverse scaffold, have had mixed success (Sonawane, et al., 2016).

Wogonin (**23**; **Figure 7**), an active flavone from the herb *Scutellaria balcalensis*, induces apoptosis in a number of cell lines and has antitumor activity in xenograft models. Wogonin and structurally related flavones are similar in structure to flavopiridol, and block the CDK9-mediated phosphorylation of the RNA polymerase II CTD at Ser2, inducing apoptosis in leukemic T-cells (Polier, et al., 2011). This induction of apoptosis is associated with a decrease in *MCL1* expression, consistent with CDK9 inhibition. Pull-down and *in silico* docking studies have demonstrated that wogonin binds to CDK9, but does not appear to inhibit CDKs 2, 4 or 6 in cells, as assessed by measurement of RB phosphorylation, at concentrations that inhibit CDK9 activity.

In separate work, a cellular screening strategy, using high content microscopy to determine effects on mitotic index and p53 induction, has been used to identify compounds that could inhibit transcription-regulating CDKs such as CDK7 and CDK9 (S. Wang, et al., 2010). This approach led to the identification of a range of inhibitors with different selectivity profiles. Subsequent optimization work resulted in the development of a CDK7/9 transcriptional inhibitor designated compound 14 in the publication (**24**; **Figure 7**). Treatment with his compound inhibited phosphorylation of the RNA polymerase II CTD at Ser2, repressed the expression of *MCL1*, induced apoptosis in several cancer cell lines and had anticancer activity in animal models. Subsequent work identified closely related compounds CDKI-71 and CDKI-73 (**25**; **Figure 7**) from a novel class of 5-substituted-4-(thiazol-5-yl)-2-(phenyl amino)pyrimidines (Shao, et al., 2013). Comparing the mechanism of action of CDKI-71 and alvodicib in human cancer cell lines, primary patient leukemia cells, B- & T-cells and embryonic lung fibroblasts, showed that both compounds were potently cytotoxic and induced caspase-dependent apoptosis (X. Liu, et al., 2012). Significantly, the CDK9-selective CDKI-71, but not the unselective alvocidib, preferentially affected cancer cells.

Chronic lymphocytic leukemia (CLL) is associated with the overexpression of genes encoding the BCL2 family of anti-apoptotic proteins. Inhibiting CDK9 expression is known to induce apoptosis in CLL cells and to increase sensitivity to fludarabine, a purine nucleoside analogue used as the standard of care for CLL (Walsby, et al., 2014). Treating primary human leukemia cells with CDKI-73 has been shown to lead to the dephosphorylation of CDK9, the dephosphorylation of the RNA polymerase II CTD at Ser2 and to induce caspase-dependent apoptosis. CDKI-73 was more potent than the pan-CDK inhibitor alvodicib, showing selectivity for primary leukemia cells over normal CD34+ cells and was synergistic with fludarabine (Walsby, et al., 2014).

LDC000067 (**26**; **Figure 7**) is another phenylamino pyrimidine inhibitor selective for CDK9, with similar cellular activity to the derivative **25** described above (Albert, et al., 2014). Treatment with LDC000067 has been shown to increase the pausing of RNA polymerase II and to lead to a selective reduction in short-lived mRNAs, including those encoding regulators of proliferation and apoptosis. Phosphorous-containing analogues of the phenylamino pyrimidines with high selectivity for CDK9 have also been described, such as compound 93 (**27**; **Figure 7**) (Nemeth, et al., 2014). Overall, the data suggests there is scope to develop selective CDK9 inhibitors such as CDKI-73 or LCD000067 as anticancer therapeutics.

5.3.4. CDK8/19

The potential role of *CDK8* as an oncogene in colorectal cancer has raised interest in the development of CDK8 inhibitors (Rzymski, Mikula, Wiklik, & Brzozka, 2015). The CDK8 and CDK19 proteins have >90% similarity over the first 370 residues, which encompass the active site, but differ substantially toward the C-terminus in areas that may contribute to their non-redundant functions. This suggests that the active site of those two proteins is very similar and compound selectivity will be a challenge. Two studies have examined

the ability of a range of compounds to bind a panel of human protein kinases and found a number of potential inhibitors of CDK8 that were selective over other CDKs (Davis, et al., 2011; Karaman, et al., 2008). These include BMS-387032/SNS-032, CP-724714, EXEL-2880/GSK-1363089, flavopiridol, PLX-4720, staurosporine and the type II inhibitors AST-487, BIRB-796, linifinib and sorafenib (**28**; **Figure 8**). Solving the crystal structure of CDK8/cyclin C subsequently revealed a unique helical recognition domain in cyclin c revealed a recognition helix, uniquely found in cyclin C, required for specific and tight binding between CDK8 and cyclin C. This work also revealed that sorafenib, a Type II inhibitor of CDK8, binds CDKs with the activation loop DF/MG-motif in an "out" conformation (**Figure 9**). This was the first example of a ligand binding to a CDK using this type of interaction (Schneider, et al., 2011).

Cortistatin A (**29**; **Figure 8**), a steroidal alkaloid isolated from the marine sponge *Corticium simplex*, has impressive antiproliferative activity in human umbilical vein endothelial cells compared to normal human dermal fibroblasts. This identified it as an attractive lead for drug discovery. Screening cortistatin A against a panel of 405 protein kinases identified a small number of kinases that it binds with high affinity, including ROCK (K_d = 220-250 nM, CDK8 (K_d = 17 nM) and CDK19 (K_d = 10 nM) (Cee, Chen, Lee, & Nicolaou, 2009). A recent follow-up study found that cortistatin A had anti-leukemic activity *in vitro* and *in vivo*, inhibited CDK8/19 activity and induced the expression of super-enhancer-associated genes in sensitive cell lines (Pelish, et al., 2015). Another screen, for inhibitors of p21-activated transcription, identified a group of compounds with a 4-aminoquinazoline scaffold as CDK8/19 inhibitors. Optimisation work yielded Senexin A (**30**; **Figure 8**), a CDK8 (K_d = 830 nM) and CDK19 (K_d = 310 nM) ligand that could inhibit beta-catenin dependent transcription, induce *EGR1* mRNA and increase the efficacy of chemotherapy against human lung carcinoma xenografts (Porter, et al., 2012). A patent (WO2013116786A1) has subsequently reported a second compound, Senexin B (**31**; **Figure 8**), with improved solubility and potency (CDK8 K_d = 140 nM, CDK19 K_d = 80 nM).

This compound inhibits p21-activated transcription and oncogenic beta-catenin activity, as described for Senexin A (Rzymski, et al., 2015). Additional compound series have been identified and described in the patent literature by Selvita (WO2014072435), Roche (WO2014029726, WO2014090692, WO2014106606, WO2014154723, and WO2015049325), Nimbus (WO2014194201) and CNIO (WO2013001310).

We have previously reported the discovery and optimization of a singleton 3,4,5-trisubstituted pyridine inhibitor of WNT signaling using a high-throughput cell-based reporter assay (Mallinger, et al., 2015). This led to the identification of CCT251545 (**32**; **Figure 8**), a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. A chemoproteomic approach identified CDK8 (IC_{50} = 5 nM) and CDK19 (IC_{50} = 6 nM) as the targets of CCT251545 with >100-fold selectivity for CDK8/19 over 293 other kinases (including CDKs 1-3, 5-7 and 9) (Dale, et al., 2015). CCT251545 is a potent inhibitor of $STAT1^{SER727}$ phosphorylation, a robust biomarker of CDK8/19 inhibition, but does not inhibit $E2F1^{SER375}$ phosphorylation or RNA polymerase CTD phosphorylation. Microarray gene expression profiling has shown that, as expected, the expression of genes regulated by CDK8/19-dependent pathways is altered in cells treated with CCT251545.

The X-ray co-crystal structure of CDK8/cyclin C revealed CCT251545 to have a Type I binding mode, which translates into potent activity in a cell-based binding assay for CDK8 and 19, and a corresponding inhibition of CDK8/19 associated-biomarkers (**Figure 9**). In contrast, three Type II binders (linifinib, ponatinib and sorafinib), with potent activity against CDK8 in biochemical enzyme assays, do not have cellular CETSA-binding or biomarker activity against CDK8. This disconnect between the data obtained from enzymatic and cell-based assays has been corroborated in a second study that used sorafenib as a starting point to develop a series of Type II inhibitors of CDK8 (**33**; **Figure 8**) (Bergeron, et al., 2016). Overall the data suggests that the *in vitro* biochemical potency

of type II inhibitors do not translate in cell-based activity, perhaps due to the association of CDK8 with MED12 and MED13. Additional CDK8/19 inhibitors have been reported in the literature, including a series of 6-aza-benzothiophene containing compounds that were developed into potent selective Type I inhibitors of CDK8 (**34**; **Figure 8**) (Koehler, et al., 2016; Rzymski, et al., 2015).

After the discovery of CCT251545 follow-up work yielded a 3,4,5-trisubstituted-2-aminopyridine series exemplified by CCT251921 (**35**; **Figure 8**). This compound is a potent selective and orally bioavailable inhibitor of CDK8, with equal affinity for CDK19 and optimal biochemical, pharmacokinetic, and physicochemical properties (Mallinger, et al., 2016). Further series of inhibitors were identified using scaffold-hop or high-throughput screening approaches, leading to the discovery of 2,8-disubstituted-1,6-naphthyridine-, 4,6-disubstituted-isoquinoline-, benzylindazole or imidazo-thiadiazole-based dual CDK8/19 ligands (**36**; **Figure 8**) (Czodrowski, et al., 2016; Mallinger, et al., 2016). Multiple cycles of structure-based design improved the microsomal stability, potency and kinase selectivity of an initial imidazo-thiadiazole scaffold, replacing it with a 3-methyl-1H-pyrazolo[3,4-b]-pyridine. This led to the identification of MSC2530818 (**36**; **Figure 8**), a compound with excellent kinase selectivity, biochemical and cellular potency, microsomal stability and oral bioavailability. MSC2530818 modulates $STAT1^{SER727}$ phosphorylation and inhibits tumor growth in an *APC* mutant SW620 human colorectal carcinoma xenograft model after oral administration. The identification of CCT251921 and MSC2530818 has provided two chemically-distinct compounds with suitable potency and selectivity for progress into preclinical efficacy and safety studies.

With potent and selective exemplar compounds from two structurally differentiated chemical series, CCT251921 and MSC2530818, and corresponding inactive control compounds, it was possible for us to investigate the therapeutic potential of dual CDK8/19 modulation. We found evidence of super-enhancer activation following CDK8/19 inhibition

in xenograft models and also that systemic and xenograft AML tumor models were particularly sensitive to treatment with these compounds, as described by Pelish and colleagues (Clarke, et al., 2016; Pelish, et al., 2015). In an *in vivo* model of an oncogenically-activated stem cell compartment we found our CDK8/19 inhibitors altered the proportion of stem cells to proliferative TA cells that may in part be due to super-enhancer activation. We also detected inhibitory effects on bone progenitor stem cells and on immune and inflammatory models *in vitro* (Clarke, et al., 2016). Importantly, we found that these CDK8/19 inhibitors had a complex toxicological profile, making it impossible to identify a clear therapeutic window for biomarker inhibition and antitumor activity (Clarke, et al., 2016). Further clinical development of these compounds has been ruled out because of their major pleiotropic toxicity, suggesting others should be cautious when considering the clinical applicability of CDK8/19 inhibitors.

5.3.5. CDK12/13

CDK12 and 13 have a key role in the regulation of gene expression; however, in the absence of CDK12/13 tool compounds, obtaining data on the role of CDK12/13 in cancerous and normal cells has involved a genetic knockout approach. Recently, THZ531, a first-in-class selective inhibitor of CDK12/13 was described (T. Zhang, et al., 2016). This compound is a covalent inhibitor, which irreversibly binds to a cysteine located outside the kinase domain of CDK12. Treatment with THZ531 led to a broad loss of gene expression, associated with reduced transcriptional elongation and a loss of RNA polymerase II CTD phosphorylation. Genes encoding proteins involved in the DNA damage response and super-enhancer-associated genes were particularly affected. Importantly, treatment with THZ531 induced apoptosis in leukemic T cells, coincident with changes in gene expression. From a therapeutic standpoint, a compound such as THZ531 is an attractive prospect for clinical development, as targeting CDK12/13 may inhibit the aberrant transcription and genomic instability that are the hallmarks of cancer. As described earlier in this review, the synthetic lethal interactions identified for loss of

CDK12 and sensitivity of human breast and ovarian cancers to tamoxifen or PARP inhibitors suggest potential stratified patient populations and combination regimes for CDK12/13 inhibitors (Bajrami, et al., 2014; Iorns, et al., 2008; P. M. Joshi, et al., 2014).

6. Conclusion and outlook

The CDKs are highly-validated targets for cancer therapeutics, because of their role in regulating critical cell cycle checkpoints and transcription. As kinases, CDKs are readily druggable and many CDK inhibitors have been described. The initially discovered ATP-competitive CDK inhibitors, such as alvocidib for example, have generally failed to progress beyond early clinical studies. Contributing factors were their poor CDK isoform selectivity, a lack of understanding of their precise mechanism of action and hence the absence of appropriate biomarkers. Particularly important was that this lack of knowledge led to a lack of patient selection biomarkers for use clinical studies, resulting in many trials being conducted in unstratified patient cohorts. Occasionally, activity in a particular tumor type has been observed in the clinic, but the underlying molecular mechanism, and hence the reason for the sensitivity of responding tumors, remains unknown. The lack of understanding of the mechanism of action of many early CDK inhibitors has also restricted their use in rational combinations with other targeted therapeutics. In addition, the inhibitors that target multiple CDKs frequently lack selectivity for cancer versus normal tissue and are not well tolerated at doses required for activity. Nevertheless, certain drugs with an appropriate mix of CDK selectivities – for example the orally-available, second generation inhibitor of cyclin dependent kinases (CDK) 2, 5 and 9 CYC065 derived from seleciclib – continue to be developed.

A real shift in attitude about the clinical use of CDK inhibitors has been the progression the CDK4/6-selective, ATP-competitive inhibitors palbociclib, abemaciclib and ribociclib –

which are either approved or in advanced registration trials for several cancers. The discovery and clinical development of these drugs, and in particular, the FDA approval for palbociclib in ER+ breast cancer, has revived serious interest in inhibitors of the cell cycle CDKs. The identification and development of selective CDK4/6 inhibitors is a major breakthrough in the treatment of metastatic breast cancer and their activity in other cancer types will be defined by the outcomes of ongoing clinical trials. In addition, the identification of tolerated and active combination regimes, patient stratification biomarkers and resistance mechanisms will contribute to our greater understanding of their potential use. Furthermore, the utility of CDK4/6 inhibition in preventing the emergence of resistance to multiple targeted therapies across various cancer types is an area of intense clinical investigation, results of which are eagerly anticipated (www.clinicaltrials.gov) (Gao, et al., 2015). The selective CDK4/6 inhibitors are exemplars for inhibitors of other CDKs targets where the identification of highly selective compounds with pharmaceutical properties is critical. Strategies exploring alternative and non-competitive approaches to CDK inhibition – such as allosteric, covalent binding and peptidomimetic mechanisms – may uncover novel pharmacology and expand the therapeutic utility of these agents. For example, MMD37K (Sanchez-Martinez, et al., 2015), a peptidomimetic derived from p16, is the first alternative class of CDK4/6 inhibitor to enter clinical studies and the data generated will allow comparisons with existing ATP-competitive inhibitors.

Perhaps surprisingly, selective inhibitors transcriptional CDKs 7 and 9 have been found to exhibit exploitable therapeutic windows for tumors compared to normal tissue in preclinical mouse models. Covalently binding inhibitors of CDK7 have shown promise in driving increased selectivity and translation of these tool compounds into clinical candidates may be deeply instructive and provide further biological insight into the varied roles of CDKs. Highly potent CDK8/19 inhibitors have been discovered, but at least for two of the chemical series tested, a lack of tolerability and therapeutic window suggests great caution when considering their clinical development and also consideration of these as

anti-targets to be avoided in other kinase inhibitors. Importantly, the availability of potent and selective tool compounds for the transcriptional CDKs will allow further exploration of their function both in disease and normal tissue homeostasis.

Finally, the identification of predictive biomarkers of response will also allow the more recently discovered CDK inhibitors to be explored in particular genetically-defined contexts, for example by building on recent observations that *KRAS* mutant tumors are highly sensitive to CDK1 inhibition, and that CDK2 or CDK9 inhibition is synthetically lethal in MYC-addicted tumor cells (Costa-Cabral, et al., 2016; Poon, et al., 2016).

Figure Legends

Figure 1. The evolutionary relationships between human CDK subfamilies determined by phylogenetic analysis based on gene sequence similarity. Conserved domains are color-coded: green, kinase domain; pink, arginine/serine-rich domain; blue, glutamic acid-rich domain; yellow, glutamine-rich domain; red, proline-rich domain. CDK11 is encoded by two separate genes, *CDK11A* and *CDK11B*, which each encode two isoforms (adapted from (Malumbres, 2014). Cyclins required for CDK activation are also indicated.

Figure 2. A simplified model of the mammalian cell cycle. Mitogenic stimulation leads to the synthesis of D-type cyclins, activating CDK4/6 and ultimately CDK2. CDKs4/6 phosphorylate the RB protein (the dotted lines indicate phosphorylation or dephosphorylation), releasing histone deacetylase1 (HDAC), which relieves repression of the transcription factor E2F1. Cyclin E is transcribed, activating CDK2, enabling further phosphorylation of RB, allowing DNA synthesis to occur. S phase is terminated when CDK2/cyclin A phosphorylates E2F1, blocking its DNA-binding ability. CDK1/cyclin B activation triggers mitosis and RB is dephosphorylated by protein phosphatase 1 (PP1). The INK4 and CIP/KIP proteins that modulate CDK activity are also indicated. The CDKs are also regulated by two families of small inhibitory proteins, INK4 and CIP/KIP, which generally act by interfering with cyclin binding (Sherr & Roberts, 1999), for example, binding of $p16^{INK4A}$, $p15^{INK4B}$, $p18^{INK4C}$ and $p19^{INK4D}$ to CDK4 blocks the interaction with cyclin D.

Figure 3. A simplified model of the transcriptional cycle of initiation, elongation and termination. RNA polymerase II undergoes multiple rounds of phosphorylation and dephosphorylation in order to coordinate its activity and bring about the synthesis of mRNAs. CDK8 has positive and negative roles in regulating transcription through effects

on specific transcription factors, super-enhancers and other transcriptional CDKs. CDK7 and CDK9 are involved in the elongation of mRNAs, while DSIF acts to block elongation and SCP1 promotes termination through dephosphorylation of Ser5 of RNA polymerase II.

Figure 4. Simplified schematic of the role of the Mediator complex and CDK8 in the initiation of transcription. The preinitiation complex forms following binding of the Mediator complex, TFIID and other general transcription factors in a step-wise manner that eventually recruits RNA polymerase II, and finally TFIIH, to the complex. The helicase activity of TFIIH opens the DNA to initiate transcription, and CDK7 activity contributes to promoter escape by breaking interactions with some factors through phosphorylation of RNA polymerase II CTD Ser5, and also Ser7. The RNA polymerase transcribes around 20-100 bases downstream of the promoter before pausing and in another regulatory process, following recruitment of the CDK8 kinase and CDK9 activation, phosphorylation of CTD Ser2 and other substrates, that loses the remaining components of the initiation complex, yielding a fully functional elongation complex (adapted from Allen & Taatjes, 2015).

Figure 5. Structure and activity of pan- or multitarget-CDK inhibitors. Table indicates IC_{50} (nM) values for each compound, with the exception of compound 4 for which K_i (nM) values are given.

Figure 6. Structure and activity of selective CDK4/6 inhibitors. Table indicates IC_{50} (nM) values.

Figure 7. Structure and activity of selective CDK7 and CDK9 inhibitors. Table indicates IC_{50} (nM) values.

Figure 8. Structures of CDK8/19 inhibitors.

Figure 9. Type I and Type II inhibitor binding to CDK8/Cyclin C. Diagram shows sorafenib (green structure, cyan compound) and CCT251545 (blue structure, magenta compound) bound to the CDK8/cyclin C complex. The DMG motif is shown in orange and is flipped “out” when bound to sorafenib and “in” when bound to CCT251545.


Associated cyclin
CDK1
A1, A2, B1, B2, D1, D3, E1, F, K
CDK2
A1, A2, B1, B2, B3, D1, D2, D3, E1, E2, G1, H, J, K
CDK3
A2, C, E1, E2
CDK5
A2, B1, D2, G1, E1, I1, I2
CDK16
Y
CDK17
Y
CDK18
K, Y
CDK14
D3, Y
CDK15
Y
CDK4
A2, D1, D2, D3, E1
CDK6
A2, D1, D2, D3, E1, T1, T2
CDK7
A2, B1, B2, E1, H
CDK8
C, H
CDK19
C
CDK10
L2
CDK11P58
D3, L1, L2
CDK11P110
L1, L2
CDK9
H, K, T1, T2A, T2B
CDK12
K
CDK13
K
CDK20
H


Mitogens
RAS
RAF-1
MEK1/2
ERK1/2
CDK4/6
D
p15INK4B
p16INK4A
p18INK4C
p19INK4D
CDK4/6
D
G0
PP1
p21CIP1
CDK1
B
M
RB
HDAC1
E2F1
RB
P
P
RB
E2F1
G1
CDK1
A
G2
P
E2F1
P
P
P
P
RB
P
P
E2F1
CDK2
E
p21CIP1
p27KIP1
p57KIP2
p21CIP1
p27KIP1
p57KIP2
CDK2
A
S
Restriction
Point


RNA Pol II
FCP1
Termination
Initiation
CDK8
C
SCP1
RNA Pol II
P
Ser2
RNA Pol II
TBP
Productive
Elongation
DSIF
Ser7
P
P
Ser5
RNA Pol II
P
Ser2
Ser7
P
P
Ser5
RNA Pol II
CDK9
T
CDK7
H
Promoter Escape
Abortive Elongation


POL II
CTD
Mediator
POL II
TFIIF
TFIIB
TFIIA
Promoter
TFIID
DNA
RNA polymerase II
recruited and TFIIH
phosphorylates CTD
Ser5
Ser7
CDK7
TFIIH
TFIIE
RNA polymerase II
exits promoter and
pauses, CDK9
phosphorylates CTD
CDK8 Mediator
CDK8 module
CDK9
Ser2
SEC
mRNA
mRNA
elongation



1 alvocidib (flavopiridol)



2 seliciclib(roscovitine)



3 dinaciclib



4 AT7519



5 RGB-286638



6 ZK-304709



7 voruciclib (P1446A-05)



8 P276-00



9 R547



10 SNS-032/BMS-387032



11 AZD5438



12 AG-024322



13 milciclib (PHA-848125)



14 roniciclib (BAY1000394)



15 TG02

CMPD	CDK1/CycB	CDK2/CycA (CDK2/CycE)	CDK4/CycD (CDK4/CycE)	CDK5/p25 (CDK5/p35)	CDK6/CycD	CDK7/CycH	CDK9/CycT
1	27	405 (282)	132		395	514	11
2	2100	100	(13500)	160	23500	540	950
3	3	1		1			4
4	190	44 (510)	67	(18)	660	2800	<100
5	480	38 (48)	925	(340)	>1000	62	4
6	2	(3)	4	(5)	55	44	1
7	50	(4)	61			85	5
8	79	224 (2543)	63		396	2870	20
9	2	(3)	1				
10	25		90				22
11	16	3 (10)	449	14	21	821	20
12	1-3	1-3	(1-3)				
13	398	45 (363)	160	(265)		150	
14	7	9	11	(<10)		25	5
15	9	5	>100	8	>100	3	37



16 palbociclib



17 abemaciclib



18 ribociclib

CMPD	CDK1/CycB	CDK2/CycA (CDK2/CycE)	CDK4/CycD (CDK4/CycE)	CDK5/p25 (CDK5/p35)	CDK6/CycD	CDK7/Cyc H	CDK9/CycT
16	>10000	>10000	11	>10000	15		
17	1627	(504)	2		10	3910	57
18	>100000	>50000	10		39		



19 LDC3140



20 LDC4297



21 THZ1



22 THZ2



23 wogonin



24 CMPD14



25 CDKI-73



26 LDC000067



27 CMPD 93

CMPD	CDK1/CycB	CDK2/CycA (CDK2/CycE)	CDK4/CycD (CDK4/CycE)	CDK5/p25 (CDK5/p35)	CDK6/CycD	CDK7/CycH	CDK9/CycT
19	>10000	3897	>10000		>10000	<5	7450
20	54	64	>10000		>10000	<5	1711
21						3.8	
22	97	222		134		14	194
23						190	12300
24	449	149	68			2	0.4
25	12	(4)			205	6	114
26	5513	2441	9242		>10000	>10000	44
27							142



28 sorafenib



29 cortistatin A



30 senexin A



31 senexin B



32 CCT251545



33 CMPD 20



34 CMPD 32



35 CCT251921



36 MSC2530818



7. References

Adler, A. S., McCleland, M. L., Truong, T., Lau, S., Modrusan, Z., Soukup, T. M., Roose-Girma, M., Blackwood, E. M., & Firestein, R. (2012). CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. *Cancer Res, 72*, 2129-2139.

Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., & Vokes, E. E. (2003). Phase II study of flavopiridol in patients with advanced colorectal cancer. *Ann Oncol, 14*, 1270-1273.

Aktas, H., Cai, H., & Cooper, G. M. (1997). Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. *Mol Cell Biol, 17*, 3850-3857.

Alarcon, C., Zaromytidou, A. I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., Sapkota, G., Pan, D., & Massague, J. (2009). Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. *Cell, 139*, 757-769.

Albanese, C., Alzani, R., Amboldi, N., Avanzi, N., Ballinari, D., Brasca, M. G., Festuccia, C., Fiorentini, F., Locatelli, G., Pastori, W., Patton, V., Roletto, F., Colotta, F., Galvani, A., Isacchi, A., Moll, J., Pesenti, E., Mercurio, C., & Ciomei, M. (2010). Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. *Mol Cancer Ther, 9*, 2243-2254.

Albert, T. K., Rigault, C., Eickhoff, J., Baumgart, K., Antrecht, C., Klebl, B., Mittler, G., & Meisterernst, M. (2014). Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. *Br J Pharmacol, 171*, 55-68.

Allen, B. L., & Taatjes, D. J. (2015). The Mediator complex: a central integrator of transcription. *Nat Rev Mol Cell Biol, 16*, 155-166.

Amita Patnaik, L. S. R., Sara M. Tolaney, Anthony W. Tolcher, Jonathan Wade Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Warren Rasco, Scott P. Myrand, Palaniappan Kulanthaivel, Joan M. Andrews, Martin Frenzel, Damien Cronier, Edward M. Chan, Keith Flaherty, Patrick Y. Wen, Geoffrey Shapiro. (2014). LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. *J Clin Oncol, 32*, abstr 534.

Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., & Sicinski, P. (2011). A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. *Cancer Cell, 20*, 620-634.

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapy. *Nat Rev Drug Discov, 14*, 130-146.

Bagella, L., Giacinti, C., Simone, C., & Giordano, A. (2006). Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle. *J Cell Biochem, 99*, 978-985.

Bahleda, R., Gazzah, A., Varga, A., Rajagopalan, P., Henderson, D. A., Kornacker, M., & Soria, J.-C. (2012). A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule. *J Clin Oncol, 30*.

Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., Chen, L., Kozarewa, I., Assiotis, I., Fenwick, K., Natrajan, R., Lord, C. J., & Ashworth, A. (2014). Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. *Cancer Res, 74*, 287-297.

Balmanno, K., & Cook, S. J. (1999). Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. *Oncogene, 18*, 3085-3097.

Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dolken, L., Strobl, B., Muller, M., Taatjes, D. J., & Kovarik, P. (2013). CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. *Immunity, 38*, 250-262.

Barriere, C., Santamaria, D., Cerqueira, A., Galan, J., Martin, A., Ortega, S., Malumbres, M., Dubus, P., & Barbacid, M. (2007). Mice thrive without Cdk4 and Cdk2. *Mol Oncol, 1*, 72-83.

Bartkowiak, B., & Greenleaf, A. L. (2011). Phosphorylation of RNAPII: To P-TEFb or not to P-TEFb? *Transcription, 2*, 115-119.

Bartkowiak, B., & Greenleaf, A. L. (2015). Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex. *J Biol Chem, 290*, 1786-1795.

Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. *Genes Dev, 24*, 2303-2316.

Bartkowiak, B., Yan, C., & Greenleaf, A. L. (2015). Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas. *Biochim Biophys Acta, 1849*, 1179-1187.

Bataille, A. R., Jeronimo, C., Jacques, P. E., Laramee, L., Fortin, M. E., Forest, A., Bergeron, M., Hanes, S. D., & Robert, F. (2012). A universal RNA polymerase II CTD cycle is orchestrated by complex interplays between kinase, phosphatase, and isomerase enzymes along genes. *Mol Cell, 45*, 158-170.

Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A., & Chen-Kiang, S. (2006). A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. *Cancer Res, 66*, 7661-7667.

Belenguer, P., Caizergues-Ferrer, M., Labbe, J. C., Doree, M., & Amalric, F. (1990). Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase. *Mol Cell Biol, 10*, 3607-3618.

Benson, C., White, J., De Bono, J., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., Cassidy, J., Gianella-Borradori, A., Judson, I., & Twelves, C. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. *Br J Cancer, 96*, 29-37.

Bergeron, P., Koehler, M. F., Blackwood, E. M., Bowman, K., Clark, K., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., Ramaswamy, S., Salphati, L., Schmidt, S., Schneider, E. V., Wu, J., & Beresini, M. (2016). Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. *ACS Med Chem Lett, 7*, 595-600.

Beyaert, R., Kidd, V. J., Cornelis, S., Van de Craen, M., Denecker, G., Lahti, J. M., Gururajan, R., Vandenabeele, P., & Fiers, W. (1997). Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor. *J Biol Chem, 272*, 11694-11697.

Blais, A., & Dynlacht, B. D. (2007). E2F-associated chromatin modifiers and cell cycle control. *Curr Opin Cell Biol, 19*, 658-662.

Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011). The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. *Genes Dev, 25*, 2158-2172.

Bose, P., Simmons, G. L., & Grant, S. (2013). Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. *Expert Opin Investig Drugs, 22*, 723-738.

Bosken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014). The structure and substrate specificity of human Cdk12/Cyclin K. *Nat Commun, 5*, 3505.

Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R. D., Chirieac, L. R., Schellens, J. H., & Shapiro, G. I. (2010). Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumors. *Ann Oncol, 21*, 884-894.

Bragelmann, J., Klumper, N., Offermann, A., von Massenhausen, A., Bohm, D., Deng, M., Queisser, A., Sanders, C., Syring, I., Merseburger, A. S., Vogel, W., Sievers, E., Vlasic, I., Carlsson, J., Andren, O., Brossart, P., Duensing, S., Svensson, M. A., Shaikhibrahim, Z., Kirfel, J., & Perner, S. (2016). Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer. *Clin Cancer Res*.

Brandeis, M., Rosewell, I., Carrington, M., Crompton, T., Jacobs, M. A., Kirk, J., Gannon, J., & Hunt, T. (1998). Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. *Proc Natl Acad Sci U S A, 95*, 4344-4349.

Brasca, M. G., Amboldi, N., Ballinari, D., Cameron, A., Casale, E., Cervi, G., Colombo, M., Colotta, F., Croci, V., D'Alessio, R., Fiorentini, F., Isacchi, A., Mercurio, C., Moretti, W., Panzeri, A., Pastori, W., Pevarello, P., Quartieri, F., Roletto, F., Traquandi, G., Vianello, P., Vulpetti, A., & Ciomei, M. (2009). Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. *J Med Chem, 52*, 5152-5163.

Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., Wainman, N., Colevas, A. D., & Eisenhauer, E. A. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. *Invest New Drugs, 22*, 315-322.

Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, A. J., Lucas, D. M., Heerema, N. A., Lozanski, G., Young, D. C., Suarez, J. R., Colevas, A. D., & Grever, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood, 109*, 399-404.

Byrd, J. C., Peterson, B. L., Gabrilove, J., Odenike, O. M., Grever, M. R., Rai, K., Larson, R. A., Cancer, & Leukemia Group, B. (2005). Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. *Clin Cancer Res, 11*, 4176-4181.

Byth, K. F., Thomas, A., Hughes, G., Forder, C., McGregor, A., Geh, C., Oakes, S., Green, C., Walker, M., Newcombe, N., Green, S., Growcott, J., Barker, A., & Wilkinson, R. W. (2009). AZD5438, a potent oral inhibitor of cyclin-dependent

kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. *Mol Cancer Ther, 8*, 1856-1866.

Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996). Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. *Cancer Res, 56*, 2973-2978.

Carrera, I., Janody, F., Leeds, N., Duveau, F., & Treisman, J. E. (2008). Pygopus activates Wingless target gene transcription through the mediator complex subunits Med12 and Med13. *Proc Natl Acad Sci U S A, 105*, 6644-6649.

Cee, V. J., Chen, D. Y., Lee, M. R., & Nicolaou, K. C. (2009). Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. *Angew Chem Int Ed Engl, 48*, 8952-8957.

Chattopadhyay, I., Singh, A., Phukan, R., Purkayastha, J., Kataki, A., Mahanta, J., Saxena, S., & Kapur, S. (2010). Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India. *Mutat Res, 696*, 130-138.

Chen, E. X., Hotte, S., Hirte, H., Siu, L. L., Lyons, J., Squires, M., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014). A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. *Br J Cancer, 111*, 2262-2267.

Chen, H. H., Wang, Y. C., & Fann, M. J. (2006). Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. *Mol Cell Biol, 26*, 2736-2745.

Chen, Z., Wang, Z., Pang, J. C., Yu, Y., Bieerkehazhi, S., Lu, J., Hu, T., Zhao, Y., Xu, X., Zhang, H., Yi, J. S., Liu, S., & Yang, J. (2016). Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. *Scientific Reports, 6*, 29090.

Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., Perez-Atayde, A., Wong, K. K., Yuan, G. C., Gray, N. S., Young, R. A., & George, R. E. (2014). CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. *Cell, 159*, 1126-1139.

Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., Zhang, J., Shimamura, T., Capelletti, M., Reibel, J. B., Cavanaugh, J. D., Gao, P., Liu, Y., Michaelsen, S. R., Poulsen, H. S., Aref, A. R., Barbie, D. A., Bradner, J. E., George, R. E., Gray, N. S., Young, R. A., & Wong, K. K. (2014). Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. *Cancer Cell, 26*, 909-922.

Clarke, P. A., Ortiz-Ruiz, M.-J., TePoele, R., Adeniji-Popoola, O., Box, G., Court, W., El Bawab, S., Esdar, C., Ewan, K., Gowan, S., de Haven Brandon, A., Hewitt, P., Hobbs, S. M., Kaufmann, W., Mallinger, A., Raynaud, F., Roe, T., Rohdich, F., Schiemann, K., Simon, S., Schneider, R., Valenti, M., Blagg, J., Blaukat, A., Dale, T., Eccles, S. A., Hecht, S., Urbahns, K., Workman, P., & and Wienke, D. (2016). Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinase. *eLife, In press*.

Classon, M., & Harlow, E. (2002). The retinoblastoma tumor suppressor in development and cancer. *Nat Rev Cancer, 2*, 910-917.

Clevers, H., & Nusse, R. (2012). Wnt/beta-catenin signaling and disease. *Cell, 149*, 1192-1205.

Cocco, E., Lopez, S., Black, J., Bellone, S., Bonazzoli, E., Predolini, F., Ferrari, F., Schwab, C. L., Menderes, G., Zammataro, L., Buza, N., Hui, P., Wong, S., Zhao, S., Bai, Y., Rimm, D. L., Ratner, E., Litkouhi, B., Silasi, D. A., Azodi, M., Schwartz, P. E., & Santin, A. D. (2016). Dual CCNE1/PIK3CA targeting is

synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas *in vitro* and *in vivo*. *Br J Cancer, 115*, 303-311.

Corden, J. L. (2013). RNA polymerase II C-terminal domain: Tethering transcription to transcript and template. *Chem Rev, 113*, 8423-8455.

Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J., Bardelli, A., Torrance, C., Lord, C. J., & Ashworth, A. (2016). CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumors. *PLoS One, 11*, e0149099.

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., Iwata, H., Harbeck, N., Zhang, K., Theall, K. P., Jiang, Y., Bartlett, C. H., Koehler, M., & Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol, 17*, 425-439.

Czodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Poeschke, O., Busch, M., Rohdich, F., Eccles, S. A., Ortiz Ruiz, M. J., Schneider, R., Raynaud, F. I., Clarke, P. A., Musil, D., Schwarz, D., Dale, T. C., Urbahns, K., Blagg, J., & Schiemann, K. (2016). Structure-based optimization of potent, selective and orally bioavailable CDK8 inhibitors discovered by high throughput screening. *J Med Chem*.

Dale, T., Clarke, P. A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M. J., Mallinger, A., Samant, R. S., Czodrowski, P., Musil, D., Schwarz, D., Schneider, K., Stubbs, M., Ewan, K., Fraser, E., TePoele, R., Court, W., Box, G., Valenti, M., de Haven Brandon, A., Gowan, S., Rohdich, F., Raynaud, F., Schneider, R., Poeschke, O., Blaukat, A., Workman, P., Schiemann, K., Eccles, S. A., Wienke, D., & Blagg, J. (2015). A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. *Nat Chem Biol, 11*, 973-980.

Davidson, G., Shen, J., Huang, Y. L., Su, Y., Karaulanov, E., Bartscherer, K., Hassler, C., Stannek, P., Boutros, M., & Niehrs, C. (2009). Cell cycle control of wnt receptor activation. *Dev Cell, 17*, 788-799.

Davidson, L., Muniz, L., & West, S. (2014). 3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. *Genes Dev, 28*, 342-356.

Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011). Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol, 29*, 1046-1051.

Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010). Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. *Oncogene, 29*, 4018-4032.

Devaiah, B. N., & Singer, D. S. (2012). Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation. *J Biol Chem, 287*, 38755-38766.

Diab, S., Eckhardt, S., Tan, A., Frenette, G., Gore, L., Depinto, W., Grippo, J., DeMario, M., Mikulski, S., & and Papadimitrakopoulou, S. (2007). A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). *J Clin Oncol, 25*, 3528.

Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L. X., Rathbone, D. D., Condy, M. M., Ustoyev, Y., Crago, A. M., Singer, S., & Schwartz, G. K. (2013). Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol, 31*, 2024-2028.

Dolman, M. E., Poon, E., Ebus, M. E., den Hartog, I. J., van Noesel, C. J., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K., Sparidans, R. W., Kok, R. J., Versteeg, R., Caron, H. N., Chesler, L., & Molenaar, J. J. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. *Clin Cancer Res, 21*, 5100-5109.

Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010). CDK8 is a positive regulator of transcriptional elongation within the serum response network. *Nat Struct Mol Biol, 17*, 194-201.

Drogat, J., & Hermand, D. (2012). Gene-specific requirement of RNA polymerase II CTD phosphorylation. *Mol Microbiol, 84*, 995-1004.

Duan, Z., Zhang, J., Choy, E., Harmon, D., Liu, X., Nielsen, P., Mankin, H., Gray, N. S., & Hornicek, F. J. (2012). Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. *Clin Cancer Res, 18*, 4580-4588.

Duarte, C. W., Willey, C. D., Zhi, D., Cui, X., Harris, J. J., Vaughan, L. K., Mehta, T., McCubrey, R. O., Khodarev, N. N., Weichselbaum, R. R., & Gillespie, G. Y. (2012). Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. *PLoS One, 7*, e29653.

Eick, D., & Geyer, M. (2013). The RNA polymerase II carboxy-terminal domain (CTD) code. *Chem Rev, 113*, 8456-8490.

Eifler, T. T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jager, S., Johnson, J. R., Luo, Z., Krogan, N. J., & Peterlin, B. M. (2015). Cyclin-dependent kinase 12 increases 3' end processing of growth factor-induced c-FOS transcripts. *Mol Cell Biol, 35*, 468-478.

Feng, Y., Sassi, S., Shen, J. K., Yang, X., Gao, Y., Osaka, E., Zhang, J., Yang, S., Yang, C., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015). Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. *J Orthop Res, 33*, 199-207.

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C., Huang, X., Kim, S. T., Randolph, S., & Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol, 16*, 25-35.

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A. R., Voytko, N. L., Huang, X., Kim, S. T., Randolph, S. S., & Slamon, D. J. (2014). Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). *Cancer Research, 74*, CT101-CT101.

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines *in vitro*. *Breast Cancer Res, 11*, R77.

Finn, R. S., Martin, M., Rugo, H. S., Jones, S. E., Im, S.-A., Gelmon, K. A., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S. L., Gauthier, E. R., Lu, D., Randolph, S., Diéras, V., & and Slamon, D. J. (2016). PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). *J Clin Oncol, 34*, abstr 507.

Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., Chheda, M. G., Tamayo, P., Finn, S., Shrestha, Y., Boehm, J. S., Jain, S., Bojarski, E., Mermel, C., Barretina, J., Chan, J. A., Baselga, J., Tabernero, J., Root, D. E., Fuchs, C. S., Loda, M., Shivdasani, R. A., Meyerson, M., & Hahn, W. C. (2008). CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. *Nature, 455*, 547-551.

Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., & Ogino, S. (2010). CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. *Int J Cancer, 126*, 2863-2873.

Fisher, R. P. (2012). The CDK Network: Linking Cycles of Cell Division and Gene Expression. *Genes Cancer, 3*, 731-738.

Flaherty, K. T., Lorusso, P. M., Demichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012). Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. *Clin Cancer Res, 18*, 568-576.

Flynn, J., Jones, J., Johnson, A. J., Andritsos, L., Maddocks, K., Jaglowski, S., Hessler, J., Grever, M. R., Im, E., Zhou, H., Zhu, Y., Zhang, D., Small, K., Bannerji, R., & Byrd, J. C. (2015). Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. *Leukemia, 29*, 1524-1529.

Frame, S., Saladino, C., Davis, S., Blake, D., & Zheleva, D. (2014). CYC065, potential therapeutic agent for AML and MLL leukaemia. *SOHO Annual Meeting Proceedings, 2*, 209.

Franck, N., Montembault, E., Rome, P., Pascal, A., Cremet, J. Y., & Giet, R. (2011). CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes. *PLoS One, 6*, e14600.

Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., Jiang, J., Bartlett, C. H., Koehler, M., Dowsett, M., Bliss, J. M., Johnston, S. R., & Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *J Clin Oncol, 34*, 2961-2968.

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., & Toogood, P. L. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol Cancer Ther, 3*, 1427-1438.

Fryer, C. J., White, J. B., & Jones, K. A. (2004). Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. *Mol Cell, 16*, 509-520.

Furuno, N., den Elzen, N., & Pines, J. (1999). Human cyclin A is required for mitosis until mid prophase. *J Cell Biol, 147*, 295-306.

Galbraith, M. D., Allen, M. A., Bensard, C. L., Wang, X., Schwinn, M. K., Qin, B., Long, H. W., Daniels, D. L., Hahn, W. C., Dowell, R. D., & Espinosa, J. M. (2013). HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. *Cell, 153*, 1327-1339.

Ganuza, M., Saiz-Ladera, C., Canamero, M., Gomez, G., Schneider, R., Blasco, M. A., Pisano, D., Paramio, J. M., Santamaria, D., & Barbacid, M. (2012). Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. *EMBO J, 31*, 2498-2510.

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., Balbin, O. A., Barbe, S., Cai, H., Casey, F., Chatterjee, S., Chiang, D. Y., Chuai, S., Cogan, S. M., Collins, S. D., Dammassa, E., Ebel, N., Embry, M., Green, J., Kauffmann, A., Kowal, C.,

Leary, R. J., Lehar, J., Liang, Y., Loo, A., Lorenzana, E., Robert McDonald 3rd, E., McLaughlin, M. E., Merkin, J., Meyer, R., Naylor, T. L., Patawaran, M., Reddy, A., Roelli, C., Ruddy, D. A., Salangsang, F., Santacroce, F., Singh, A. P., Tang, Y., Tinetto, W., Tobler, S., Velazquez, R., Venkatesan, K., Von Arx, F., Wang, H. Q., Wang, Z., Wiesmann, M., Wyss, D., Xu, F., Bitter, H., Atadja, P., Lees, E., Hofmann, F., Li, E., Keen, N., Cozens, R., Jensen, M. R., Pryer, N. K., Williams, J. A., & Sellers, W. R. (2015). High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med*.

Garriga, J., Xie, H., Obradovic, Z., & Grana, X. (2010). Selective control of gene expression by CDK9 in human cells. *J Cell Physiol, 222*, 200-208.

Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., Del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., Neubauer, B. L., Young, J., Chan, E. M., Iversen, P., Cronier, D., Kreklau, E., & de Dios, A. (2014). Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. *Invest New Drugs, 32*, 825-837.

Ghia, P., Scarfo, L., Pathiraja, K., Derosier, M., Small, K., & Patton, N. (2015). A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia. *Blood, 126*, 4171-4171.

Goh, K. C., Novotny-Diermayr, V., Hart, S., Ong, L. C., Loh, Y. K., Cheong, A., Tan, Y. C., Hu, C., Jayaraman, R., William, A. D., Sun, E. T., Dymock, B. W., Ong, K. H., Ethirajulu, K., Burrows, F., & Wood, J. M. (2012). TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. *Leukemia, 26*, 236-243.

Gopinathan, L., Tan, S. L., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P. (2014). Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. *Cancer Res, 74*, 3870-3879.

Gu, W., Wang, C., Li, W., Hsu, F. N., Tian, L., Zhou, J., Yuan, C., Xie, X. J., Jiang, T., Addya, S., Tai, Y., Kong, B., & Ji, J. Y. (2013). Tumor-suppressive effects of CDK8 in endometrial cancer cells. *Cell Cycle, 12*, 987-999.

Guen, V. J., Gamble, C., Flajolet, M., Unger, S., Thollet, A., Ferandin, Y., Superti-Furga, A., Cohen, P. A., Meijer, L., & Colas, P. (2013). CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. *Proc Natl Acad Sci U S A, 110*, 19525-19530.

Gupta, K., Sari-Ak, D., Haffke, M., Trowitzsch, S., & Berger, I. (2016). Zooming in on Transcription Preinitiation. *J Mol Biol, 428*, 2581-2591.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell, 144*, 646-674.

Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., Puyana Theall, K., Bartlett, C. H., & Loibl, S. (2016). Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. *Ann Oncol, 27*, 1047-1054.

Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A., & Dean, D. C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell, 98*, 859-869.

Heath, E. I., Bible, K., Martell, R. E., Adelman, D. C., & Lorusso, P. M. (2008). A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. *Invest New Drugs, 26*, 59-65.

Helin, K. (1998). Regulation of cell proliferation by the E2F transcription factors. *Curr Opin Genet Dev, 8*, 28-35.

Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., Bellet, M., Cortes, J., Elliott, R., Pancholi, S., Baselga, J., Dowsett, M., Martin, L. A., Turner, N. C., & Serra, V. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. *Cancer Res, 76*, 2301-2313.

Hossain, D. M. S., Ugarte, F., Sawant, A., Cai, M., Sriram, V., Pinheiro, E., Sadekova, S., & Chackerian, A. (2016). Abstract 562: Dinaciclib induces immunogenic cell death and enhances anti-PD-1 mediated tumor suppression. *Cancer Research, 76*, 562-562.

Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (2003). CDK11 complexes promote pre-mRNA splicing. *J Biol Chem, 278*, 8623-8629.

Huang, C. H., Lujambio, A., Zuber, J., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T., Zhu, N., de Stanchina, E., Sawyers, C. L., Armstrong, S. A., Lewis, J. S., Sherr, C. J., & Lowe, S. W. (2014). CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. *Genes Dev, 28*, 1800-1814.

Huang, J., Deng, Q., Wang, Q., Li, K. Y., Dai, J. H., Li, N., Zhu, Z. D., Zhou, B., Liu, X. Y., Liu, R. F., Fei, Q. L., Chen, H., Cai, B., Zhou, B., Xiao, H. S., Qin, L. X., & Han, Z. G. (2012). Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. *Nat Genet, 44*, 1117-1121.

Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., Parasuraman, S., & Shapiro, G. I. (2016). A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas. *Clin Cancer Res*.

Iorns, E., Martens-de Kemp, S. R., Lord, C. J., & Ashworth, A. (2009). CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. *Carcinogenesis, 30*, 1696-1701.

Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N., Crook, T., Lord, C. J., & Ashworth, A. (2008). Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. *Cancer Cell, 13*, 91-104.

Jasnovidova, O., & Stefl, R. (2013). The CTD code of RNA polymerase II: a structural view. *Wiley Interdiscip Rev RNA, 4*, 1-16.

Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., & Pavletich, N. P. (1995). Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. *Nature, 376*, 313-320.

Jeronimo, C., Bataille, A. R., & Robert, F. (2013). The writers, readers, and functions of the RNA polymerase II C-terminal domain code. *Chem Rev, 113*, 8491-8522.

Jeronimo, C., Collin, P., & Robert, F. (2016). The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. *J Mol Biol, 428*, 2607-2622.

Jia, B., Choy, E., Cote, G., Harmon, D., Ye, S., Kan, Q., Mankin, H., Hornicek, F., & Duan, Z. (2014). Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. *Cancer Lett, 342*, 104-112.

Johnson, N., Cai, D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y. C., D'Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009). Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. *Mol Cell, 35*, 327-339.

Johnson, N., Li, Y. C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., Newell, D. R., D'Andrea, A. D., Curtin, N. J., Wong, K. K., & Shapiro, G. I. (2011). Compromised CDK1

activity sensitizes BRCA-proficient cancers to PARP inhibition. *Nat Med, 17*, 875-882.

Joshi, K. S., Rathos, M. J., Joshi, R. D., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, B., & Sharma, S. (2007). *In vitro* antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. *Mol Cancer Ther, 6*, 918-925.

Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014). Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. *J Biol Chem, 289*, 9247-9253.

Juan, H. C., Lin, Y., Chen, H. R., & Fann, M. J. (2016). Cdk12 is essential for embryonic development and the maintenance of genomic stability. *Cell Death Differ, 23*, 1038-1048.

Kalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., & Costa, R. H. (2004). Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. *Genes Dev, 18*, 830-850.

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., & Zarrinkar, P. P. (2008). A quantitative analysis of kinase inhibitor selectivity. *Nat Biotechnol, 26*, 127-132.

Kasten, M., & Giordano, A. (2001). Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. *Oncogene, 20*, 1832-1838.

Kauraniemi, P., Barlund, M., Monni, O., & Kallioniemi, A. (2001). New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. *Cancer Res, 61*, 8235-8240.

Kauraniemi, P., Kuukasjarvi, T., Sauter, G., & Kallioniemi, A. (2003). Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. *Am J Pathol, 163*, 1979-1984.

Kelso, T. W., Baumgart, K., Eickhoff, J., Albert, T., Antrecht, C., Lemcke, S., Klebl, B., & Meisterernst, M. (2014). Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. *Mol Cell Biol, 34*, 3675-3688.

Khodarev, N. N., Beckett, M., Labay, E., Darga, T., Roizman, B., & Weichselbaum, R. R. (2004). STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. *Proc Natl Acad Sci U S A, 101*, 1714-1719.

Khodarev, N. N., Roizman, B., & Weichselbaum, R. R. (2012). Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. *Clin Cancer Res, 18*, 3015-3021.

Kim, M. Y., Han, S. I., & Lim, S. C. (2011). Roles of cyclin-dependent kinase 8 and beta-catenin in the oncogenesis and progression of gastric adenocarcinoma. *Int J Oncol, 38*, 1375-1383.

Kim, S., Xu, X., Hecht, A., & Boyer, T. G. (2006). Mediator is a transducer of Wnt/beta-catenin signaling. *J Biol Chem, 281*, 14066-14075.

Knuesel, M. T., Meyer, K. D., Donner, A. J., Espinosa, J. M., & Taatjes, D. J. (2009). The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. *Mol Cell Biol, 29*, 650-661.

Ko, T. K., Kelly, E., & Pines, J. (2001). CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. *J Cell Sci, 114*, 2591-2603.

Koehler, M. F., Bergeron, P., Blackwood, E. M., Bowman, K., Clark, K. R., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., Salphati, L., Schmidt, S., Schneider, E. V., Wu, J., & Beresini, M. H. (2016). Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. *ACS Med Chem Lett, 7*, 223-228.

Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., Akashi, K., & Sicinski, P. (2004). Mouse development and cell proliferation in the absence of D-cyclins. *Cell, 118*, 477-491.

Kren, B. T., Unger, G. M., Abedin, M. J., Vogel, R. I., Henzler, C. M., Ahmed, K., & Trembley, J. H. (2015). Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. *Breast Cancer Res, 17*, 19.

Kumar, S. K., LaPlant, B., Chng, W. J., Zonder, J., Callander, N., Fonseca, R., Fruth, B., Roy, V., Erlichman, C., & Stewart, A. K. (2015). Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. *Blood, 125*, 443-448.

Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., Jenkins, C. E., Hannett, N. M., McMillin, D., Sanda, T., Sim, T., Kim, N. D., Look, T., Mitsiades, C. S., Weng, A. P., Brown, J. R., Benes, C. H., Marto, J. A., Young, R. A., & Gray, N. S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature, 511*, 616-620.

Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., Bender, R. P., Chu, G. C., Flaherty, K. T., Wargo, J. A., Collins, J. J., & Chin, L. (2012). Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. *Nat Med, 18*, 1503-1510.

Lam, F., Abbas, A. Y., Shao, H., Teo, T., Adams, J., Li, P., Bradshaw, T. D., Fischer, P. M., Walsby, E., Pepper, C., Chen, Y., Ding, J., & Wang, S. (2014). Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. *Oncotarget, 5*, 7691-7704.

Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., & Staudt, L. M. (2001). Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. *Genome Biol, 2*, RESEARCH0041.

Laoukili, J., Alvarez, M., Meijer, L. A., Stahl, M., Mohammed, S., Kleij, L., Heck, A. J., & Medema, R. H. (2008). Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. *Mol Cell Biol, 28*, 3076-3087.

Larochelle, S., Amat, R., Glover-Cutter, K., Sanso, M., Zhang, C., Allen, J. J., Shokat, K. M., Bentley, D. L., & Fisher, R. P. (2012). Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. *Nat Struct Mol Biol, 19*, 1108-1115.

Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., & Pouyssegur, J. (1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. *J Biol Chem, 271*, 20608-20616.

Le Tourneau, C., Faivre, S., Laurence, V., Delbaldo, C., Vera, K., Girre, V., Chiao, J., Armour, S., Frame, S., Green, S. R., Gianella-Borradori, A., Dieras, V., & Raymond, E. (2010). Phase I evaluation of seliciclib (R-roscovitine), a novel

oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. *Eur J Cancer, 46*, 3243-3250.

Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., Kwong, L. N., & Kopetz, S. (2016). Efficacy of the combination of MEK and CDK4/6 inhibitors *in vitro* and *in vivo* in KRAS mutant colorectal cancer models. *Oncotarget*.

Leung, W. K., Ching, A. K., Chan, A. W., Poon, T. C., Mian, H., Wong, A. S., To, K. F., & Wong, N. (2011). A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. *Oncogene, 30*, 4464-4475.

Li, B., Carey, M., & Workman, J. L. (2007). The role of chromatin during transcription. *Cell, 128*, 707-719.

Liang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015). Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. *Mol Cell Biol, 35*, 928-938.

Liu, G., Gandara, D. R., Lara, P. N., Jr., Raghavan, D., Doroshow, J. H., Twardowski, P., Kantoff, P., Oh, W., Kim, K., & Wilding, G. (2004). A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. *Clin Cancer Res, 10*, 924-928.

Liu, M., Dai, B., Kang, S. H., Ban, K., Huang, F. J., Lang, F. F., Aldape, K. D., Xie, T. X., Pelloski, C. E., Xie, K., Sawaya, R., & Huang, S. (2006). FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. *Cancer Res, 66*, 3593-3602.

Liu, X., Shi, S., Lam, F., Pepper, C., Fischer, P. M., & Wang, S. (2012). CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. *Int J Cancer, 130*, 1216-1226.

Liu, Y., Ranish, J. A., Aebersold, R., & Hahn, S. (2001). Yeast nuclear extract contains two major forms of RNA polymerase II mediator complexes. *J Biol Chem, 276*, 7169-7175.

Loyer, P., Trembley, J. H., Grenet, J. A., Busson, A., Corlu, A., Zhao, W., Kocak, M., Kidd, V. J., & Lahti, J. M. (2008). Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. *J Biol Chem, 283*, 7721-7732.

Loyer, P., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (1998). The RNP protein, RNPS1, associates with specific isoforms of the p34cdc2-related PITSLRE protein kinase *in vivo*. *J Cell Sci, 111 (Pt 11)*, 1495-1506.

MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005). Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. *Cancer Res, 65*, 5399-5407.

Mahadevan, D., Plummer, R., Squires, M. S., Rensvold, D., Kurtin, S., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D. M., Von Hoff, D., & Calvert, H. (2011). A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. *Ann Oncol, 22*, 2137-2143.

Mallinger, A., Crumpler, S., Pichowicz, M., Waalboer, D., Stubbs, M., Adeniji-Popoola, O., Wood, B., Smith, E., Thai, C., Henley, A. T., Georgi, K., Court, W., Hobbs, S., Box, G., Ortiz-Ruiz, M. J., Valenti, M., De Haven Brandon, A., TePoele, R., Leuthner, B., Workman, P., Aherne, W., Poeschke, O., Dale, T., Wienke, D., Esdar, C., Rohdich, F., Raynaud, F., Clarke, P. A., Eccles, S. A., Stieber, F., Schiemann, K., & Blagg, J. (2015). Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. *J Med Chem, 58*, 1717-1735.

Mallinger, A., Schiemann, K., Rink, C., Stieber, F., Calderini, M., Crumpler, S., Stubbs, M., Adeniji-Popoola, O., Poeschke, O., Busch, M., Czodrowski, P., Musil, D., Schwarz, D., Ortiz-Ruiz, M. J., Schneider, R., Thai, C., Valenti, M., de Haven Brandon, A., Burke, R., Workman, P., Dale, T., Wienke, D., Clarke, P. A., Esdar, C., Raynaud, F. I., Eccles, S. A., Rohdich, F., & Blagg, J. (2016). Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. *J Med Chem, 59*, 1078-1101.

Malumbres, M. (2014). Cyclin-dependent kinases. *Genome Biol, 15*, 122.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer, 9*, 153-166.

Malumbres, M., Harlow, E., Hunt, T., Hunter, T., Lahti, J. M., Manning, G., Morgan, D. O., Tsai, L. H., & Wolgemuth, D. J. (2009). Cyclin-dependent kinases: a family portrait. *Nat Cell Biol, 11*, 1275-1276.

Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004). Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell, 118*, 493-504.

Marais, A., Ji, Z., Child, E. S., Krause, E., Mann, D. J., & Sharrocks, A. D. (2010). Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes. *J Biol Chem, 285*, 35728-35739.

Marshall, C. (1999). How do small GTPase signal transduction pathways regulate cell cycle entry? *Curr Opin Cell Biol, 11*, 732-736.

Marzec, M., Kasprzycka, M., Lai, R., Gladden, A. B., Wlodarski, P., Tomczak, E., Nowell, P., Deprimo, S. E., Sadis, S., Eck, S., Schuster, S. J., Diehl, J. A., & Wasik, M. A. (2006). Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. *Blood, 108*, 1744-1750.

Mayer, A., Lidschreiber, M., Siebert, M., Leike, K., Soding, J., & Cramer, P. (2010). Uniform transitions of the general RNA polymerase II transcription complex. *Nat Struct Mol Biol, 17*, 1272-1278.

McCleland, M. L., Soukup, T. M., Liu, S. D., Esensten, J. H., de Sousa e Melo, F., Yaylaoglu, M., Warming, S., Roose-Girma, M., & Firestein, R. (2015). Cdk8 deletion in the Apc(Min) murine tumor model represses EZH2 activity and accelerates tumorigenesis. *J Pathol, 237*, 508-519.

Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., & Moulinoux, J. P. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. *Eur J Biochem, 243*, 527-536.

Merrick, K. A., Wohlbold, L., Zhang, C., Allen, J. J., Horiuchi, D., Huskey, N. E., Goga, A., Shokat, K. M., & Fisher, R. P. (2011). Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. *Mol Cell, 42*, 624-636.

Meyer, K. D., Donner, A. J., Knuesel, M. T., York, A. G., Espinosa, J. M., & Taatjes, D. J. (2008). Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. *EMBO J, 27*, 1447-1457.

Mikolajczyk, M., Shi, J., Vaillancourt, R. R., Sachs, N. A., & Nelson, M. (2003). The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM. *Biochem Biophys Res Commun, 310*, 14-18.

Mita, M. M., Joy, A. A., Mita, A., Sankhala, K., Jou, Y. M., Zhang, D., Statkevich, P., Zhu, Y., Yao, S. L., Small, K., Bannerji, R., & Shapiro, C. L. (2014). Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. *Clin Breast Cancer, 14*, 169-176.

Mitra, A. P., Almal, A. A., George, B., Fry, D. W., Lenehan, P. F., Pagliarulo, V., Cote, R. J., Datar, R. H., & Worzel, W. P. (2006). The use of genetic

programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. *BMC Cancer, 6*, 159.

Mittnacht, S., Lees, J. A., Desai, D., Harlow, E., Morgan, D. O., & Weinberg, R. A. (1994). Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. *EMBO J*, *13*, 118-127.

Morris, E. J., Ji, J. Y., Yang, F., Di Stefano, L., Herr, A., Moon, N. S., Kwon, E. J., Haigis, K. M., Naar, A. M., & Dyson, N. J. (2008). E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. *Nature, 455*, 552-556.

Mueller, P. R., Coleman, T. R., Kumagai, A., & Dunphy, W. G. (1995). Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. *Science, 270*, 86-90.

Murphy, M., Stinnakre, M. G., Senamaud-Beaufort, C., Winston, N. J., Sweeney, C., Kubelka, M., Carrington, M., Brechot, C., & Sobczak-Thepot, J. (1997). Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. *Nat Genet, 15*, 83-86.

Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014). Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. *eLife*, *3*, e02872.

Nemeth, G., Greff, Z., Sipos, A., Varga, Z., Szekely, R., Sebestyen, M., Jaszay, Z., Beni, S., Nemes, Z., Pirat, J. L., Volle, J. N., Virieux, D., Gyuris, A., Kelemenics, K., Ay, E., Minarovits, J., Szathmary, S., Keri, G., & Orfi, L. (2014). Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors. *J Med Chem, 57*, 3939-3965.

Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y. M., Statkevich, P., Yao, S. L., & Bannerji, R. (2013). A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. *J Transl Med, 11*, 259.

Nilson, K. A., Guo, J., Turek, M. E., Brogie, J. E., Delaney, E., Luse, D. S., & Price, D. H. (2015). THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. *Mol Cell, 59*, 576-587.

Nurse, P. (2000). A long twentieth century of the cell cycle and beyond. *Cell, 100*, 71-78.

Ortega, S., Prieto, I., Odajima, J., Martin, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003). Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. *Nat Genet, 35*, 25-31.

Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., & Draetta, G. (1992). Cyclin A is required at two points in the human cell cycle. *EMBO J, 11*, 961-971.

Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., Nomeir, A., Windsor, W., Fischmann, T., Wang, Y., Oft, M., Chen, T., Kirschmeier, P., & Lees, E. M. (2010). Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. *Mol Cancer Ther, 9*, 2344-2353.

Patel, H., Abduljabbar, R., Lai, C. F., Periyasamy, M., Harrod, A., Gemma, C., Steel, J., Patel, N., Busonero, C., Jerjees, D., Remenyi, J., Smith, S., Gomm, J. J., Magnani, L., Gyorffy, B., Jones, J. L., Fuller-Pace, F. V., Shousha, S., Buluwela, L., Rakha, E. A., Ellis, I. O., Coombes, R. C., & Ali, S. (2016). CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer. *Clin Cancer Res*.

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty,

K. T., Wen, P. Y., & Shapiro, G. I. (2016). Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov, 6*, 740-753.

Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., & Ewen, M. E. (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. *Nature, 386*, 177-181.

Pelish, H. E., Liau, B. B., Nitulescu, II, Tangpeerachaikul, A., Poss, Z. C., Da Silva, D. H., Caruso, B. T., Arefolov, A., Fadeyi, O., Christie, A. L., Du, K., Banka, D., Schneider, E. V., Jestel, A., Zou, G., Si, C., Ebmeier, C. C., Bronson, R. T., Krivtsov, A. V., Myers, A. G., Kohl, N. E., Kung, A. L., Armstrong, S. A., Lemieux, M. E., Taatjes, D. J., & Shair, M. D. (2015). Mediator kinase inhibition further activates super-enhancer-associated genes in AML. *Nature, 526*, 273-276.

Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., & Nigg, E. A. (1990a). Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. *Cell, 60*, 791-801.

Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., & Nigg, E. A. (1990b). *In vitro* disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase. *Cell, 61*, 591-602.

Petretti, C., Savoian, M., Montembault, E., Glover, D. M., Prigent, C., & Giet, R. (2006). The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. *EMBO Rep, 7*, 418-424.

Polier, G., Ding, J., Konkimalla, B. V., Eick, D., Ribeiro, N., Kohler, R., Giaisi, M., Efferth, T., Desaubry, L., Krammer, P. H., & Li-Weber, M. (2011). Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. *Cell Death Dis, 2*, e182.

Poon, E., Jamin, Y., Walz, S., Hakkert, S., Kwok, C., Hallsworth, A., Thway, K., Barker, K., Sbirkov, Y., Pickard, L., Urban, Z., Tardif, N., Webber, H., Box, G., Valenti, M., De Haven Brandon, A., Petrie, K., Ebus, M., Molenaar, J., Eccles, S., Robinson, S. P., Zheleva, D., Eilers, M., Workman, P., & Chesler, L. (2016). The small molecule CDK2 and CDK9 inhibitors CYC065 and CCT68127 are potent inhibitors of MYCN via transcriptional repression. *Childhood Cancer Meeting 2016, September 5 – 7, London, UK*, Abs. 1-19.

Porter, D. C., Farmaki, E., Altilia, S., Schools, G. P., West, D. K., Chen, M., Chang, B. D., Puzyrev, A. T., Lim, C. U., Rokow-Kittell, R., Friedhoff, L. T., Papavassiliou, A. G., Kalurupalle, S., Hurteau, G., Shi, J., Baran, P. S., Gyorffy, B., Wentland, M. P., Broude, E. V., Kiaris, H., & Roninson, I. B. (2012). Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. *Proc Natl Acad Sci U S A, 109*, 13799-13804.

Poss, Z. C., Ebmeier, C. C., & Taatjes, D. J. (2013). The Mediator complex and transcription regulation. *Crit Rev Biochem Mol Biol, 48*, 575-608.

Pozo, K., Castro-Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V., Meyer, D., Guo, A., Gundara, J., Mettlach, G., Richer, E., Guevara, J. A., Ning, L., Gupta, A., Hao, G., Tsai, L. H., Sun, X., Antich, P., Sidhu, S., Robinson, B. G., Chen, H., Nwariaku, F. E., Pfragner, R., Richardson, J. A., & Bibb, J. A. (2013). The role of Cdk5 in neuroendocrine thyroid cancer. *Cancer Cell, 24*, 499-511.

Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., Pickl, W. F., Zebedin-Brandl, E. M., Muller, M., Decker, T., & Sexl, V. (2013). CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. *Cell Rep, 4*, 437-444.

Puyol, M., Martin, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaria, D., & Barbacid, M. (2010). A synthetic lethal interaction between

K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. *Cancer Cell, 18*, 63-73.

Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., Kim, S., Parasuraman, S., Caponigro, G., Schnepp, R. W., Wood, A. C., Pawel, B., Cole, K. A., & Maris, J. M. (2013). Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. *Clin Cancer Res, 19*, 6173-6182.

Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., & Johnson, M. D. (2007). MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. *Breast Cancer Res Treat, 104*, 13-19.

Rakkaa, T., Escude, C., Giet, R., Magnaghi-Jaulin, L., & Jaulin, C. (2014). CDK11(p58) kinase activity is required to protect sister chromatid cohesion at centromeres in mitosis. *Chromosome Res, 22*, 267-276.

Ramakrishnan, R., & Rice, A. P. (2012). Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway. *J Cell Physiol, 227*, 609-617.

Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. *Nat Genet, 22*, 44-52.

Raynaud, F. I., Whittaker, S. R., Fischer, P. M., McClue, S., Walton, M. I., Barrie, S. E., Garrett, M. D., Rogers, P., Clarke, S. J., Kelland, L. R., Valenti, M., Brunton, L., Eccles, S., Lane, D. P., & Workman, P. (2005). *In vitro* and *in vivo* pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. *Clin Cancer Res, 11*, 4875-4887.

Rocha, P. P., Scholze, M., Bleiss, W., & Schrewe, H. (2010). Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. *Development, 137*, 2723-2731.

Rodgers, J. T., King, K. Y., Brett, J. O., Cromie, M. J., Charville, G. W., Maguire, K. K., Brunson, C., Mastey, N., Liu, L., Tsai, C. R., Goodell, M. A., & Rando, T. A. (2014). mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). *Nature, 510*, 393-396.

Rossi, D. J., Londesborough, A., Korsisaari, N., Pihlak, A., Lehtonen, E., Henkemeyer, M., & Makela, T. P. (2001). Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. *EMBO J, 20*, 2844-2856.

Russo, A. A., Jeffrey, P. D., & Pavletich, N. P. (1996). Structural basis of cyclin-dependent kinase activation by phosphorylation. *Nat Struct Biol, 3*, 696-700.

Rzymski, T., Mikula, M., Wiklik, K., & Brzozka, K. (2015). CDK8 kinase--An emerging target in targeted cancer therapy. *Biochim Biophys Acta, 1854*, 1617-1629.

Sadasivam, S., Duan, S., & DeCaprio, J. A. (2012). The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. *Genes Dev, 26*, 474-489.

Sanchez-Martinez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015). Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. *Bioorg Med Chem Lett, 25*, 3420-3435.

Santamaria, D., Barriere, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Caceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007). Cdk1 is sufficient to drive the mammalian cell cycle. *Nature, 448*, 811-815.

Scaltriti, M., Eichhorn, P. J., Cortes, J., Prudkin, L., Aura, C., Jimenez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., Guzman, M., Gili, M., Rodriguez, O., Rodriguez, S., Perez, J., Green, S. R., Mai, S., Rosen, N., Hudis, C., & Baselga, J. (2011). Cyclin E amplification/overexpression is a

mechanism of trastuzumab resistance in HER2+ breast cancer patients. *Proc Natl Acad Sci U S A, 108*, 3761-3766.

Schneider, E. V., Bottcher, J., Blaesse, M., Neumann, L., Huber, R., & Maskos, K. (2011). The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. *J Mol Biol, 412*, 251-266.

Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., & Kelsen, D. (2001). Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. *J Clin Oncol, 19*, 1985-1992.

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011). Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). *Br J Cancer, 104*, 1862-1868.

Seo, J. O., Han, S. I., & Lim, S. C. (2010). Role of CDK8 and beta-catenin in colorectal adenocarcinoma. *Oncol Rep, 24*, 285-291.

Shao, H., Shi, S., Huang, S., Hole, A. J., Abbas, A. Y., Baumli, S., Liu, X., Lam, F., Foley, D. W., Fischer, P. M., Noble, M., Endicott, J. A., Pepper, C., & Wang, S. (2013). Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. *J Med Chem, 56*, 640-659.

Sherr, C. J. (1996). Cancer cell cycles. *Science, 274*, 1672-1677.

Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev, 13*, 1501-1512.

Shi, J., Feng, Y., Goulet, A. C., Vaillancourt, R. R., Sachs, N. A., Hershey, J. W., & Nelson, M. A. (2003). The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. *J Biol Chem, 278*, 5062-5071.

Shiraishi, Y., Fujimoto, A., Furuta, M., Tanaka, H., Chiba, K., Boroevich, K. A., Abe, T., Kawakami, Y., Ueno, M., Gotoh, K., Ariizumi, S., Shibuya, T., Nakano, K., Sasaki, A., Maejima, K., Kitada, R., Hayami, S., Shigekawa, Y., Marubashi, S., Yamada, T., Kubo, M., Ishikawa, O., Aikata, H., Arihiro, K., Ohdan, H., Yamamoto, M., Yamaue, H., Chayama, K., Tsunoda, T., Miyano, S., & Nakagawa, H. (2014). Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. *PLoS One, 9*, e114263.

Siemeister, G., Lucking, U., Wengner, A. M., Lienau, P., Steinke, W., Schatz, C., Mumberg, D., & Ziegelbauer, K. (2012). BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. *Mol Cancer Ther, 11*, 2265-2273.

Sonawane, Y. A., Taylor, M. A., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016). Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. *J Med Chem*.

Squires, M. S., Cooke, L., Lock, V., Qi, W., Lewis, E. J., Thompson, N. T., Lyons, J. F., & Mahadevan, D. (2010). AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. *Mol Cancer Ther, 9*, 920-928.

Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D. M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009). Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. *Mol Cancer Ther, 8*, 324-332.

Storch, K., & Cordes, N. (2016). The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells. *Int J Oncol, 48*, 191-198.

Strelkov, I. S., & Davie, J. R. (2002). Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. *Cancer Res, 62*, 75-78.

Sun, T., Co, N. N., & Wong, N. (2014). PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. *Biochem Biophys Res Commun, 449*, 163-168.

Taatjes, D. J., Naar, A. M., Andel, F., 3rd, Nogales, E., & Tjian, R. (2002). Structure, function, and activator-induced conformations of the CRSP coactivator. *Science, 295*, 1058-1062.

Takahashi, H., Parmely, T. J., Sato, S., Tomomori-Sato, C., Banks, C. A., Kong, S. E., Szutorisz, H., Swanson, S. K., Martin-Brown, S., Washburn, M. P., Florens, L., Seidel, C. W., Lin, C., Smith, E. R., Shilatifard, A., Conaway, R. C., & Conaway, J. W. (2011). Human mediator subunit MED26 functions as a docking site for transcription elongation factors. *Cell, 146*, 92-104.

Tetsu, O., & McCormick, F. (2003). Proliferation of cancer cells despite CDK2 inhibition. *Cancer Cell, 3*, 233-245.

Tiedemann, R. E., Zhu, Y. X., Schmidt, J., Shi, C. X., Sereduk, C., Yin, H., Mousses, S., & Stewart, A. K. (2012). Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. *Cancer Res, 72*, 757-768.

Tiedemann, R. E., Zhu, Y. X., Schmidt, J., Yin, H., Shi, C. X., Que, Q., Basu, G., Azorsa, D., Perkins, L. M., Braggio, E., Fonseca, R., Bergsagel, P. L., Mousses, S., & Stewart, A. K. (2010). Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. *Blood, 115*, 1594-1604.

Tolaney, S. M., Hilton, J. F., Cleary, J. M., Gandhi, L., Kwak, E. L., Clark, J. W., Wolanski, A., Bell, T. D., Rodig, S. J., Chiao, J. H., Blake, D., & and Shapiro, G. (2016). Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. *J Clin Oncol, 34*, abstr 2503.

Tong, W. G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L., Coutre, S., Fox, J. A., Mahadocon, K., Chen, T., Kegley, P., Hoch, U., & Wierda, W. G. (2010). Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. *J Clin Oncol, 28*, 3015-3022.

Treiber, D. K., & Shah, N. P. (2013). Ins and outs of kinase DFG motifs. *Chem Biol, 20*, 745-746.

Trembley, J. H., Hu, D., Hsu, L. C., Yeung, C. Y., Slaughter, C., Lahti, J. M., & Kidd, V. J. (2002). PITSLRE p110 protein kinases associate with transcription complexes and affect their activity. *J Biol Chem, 277*, 2589-2596.

Trembley, J. H., Loyer, P., Hu, D., Li, T., Grenet, J., Lahti, J. M., & Kidd, V. J. (2004). Cyclin dependent kinase 11 in RNA transcription and splicing. *Prog Nucleic Acid Res Mol Biol, 77*, 263-288.

Tsai, K. L., Sato, S., Tomomori-Sato, C., Conaway, R. C., Conaway, J. W., & Asturias, F. J. (2013). A conserved Mediator-CDK8 kinase module association regulates Mediator-RNA polymerase II interaction. *Nat Struct Mol Biol, 20*, 611-619.

Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999). Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. *Mol Cell Biol, 19*, 7011-7019.

Tsutsui, T., Umemura, H., Tanaka, A., Mizuki, F., Hirose, Y., & Ohkuma, Y. (2008). Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-dependent transcriptional regulation. *Genes Cells, 13*, 817-826.

Turner, N. C., Ro, J., Andre, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M.,

Cristofanilli, M., & Group, P. S. (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *N Engl J Med, 373*, 209-219.

van den Heuvel, S., & Harlow, E. (1993). Distinct roles for cyclin-dependent kinases in cell cycle control. *Science, 262*, 2050-2054.

Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., Zhang, K., Thiele, A., Turner, N. C., & Rugo, H. S. (2016). Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). *Oncologist, 21*, 1165-1175.

Viladevall, L., St Amour, C. V., Rosebrock, A., Schneider, S., Zhang, C., Allen, J. J., Shokat, K. M., Schwer, B., Leatherwood, J. K., & Fisher, R. P. (2009). TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. *Mol Cell, 33*, 738-751.

Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., Lehar, J., Wiesmann, M., Wartmann, M., Chen, Y., Cao, Z. A., Pinzon-Ortiz, M., Kim, S., Schlegel, R., Huang, A., & Engelman, J. A. (2014). CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. *Cancer Cell, 26*, 136-149.

W. Yeo, B. G., C. Le Tourneau, S. R. Green, J. H. Chiao, L. L. Siu. (2009). A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. *J Clin Oncol, 27*, abstr 6026.

Walsby, E., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P. M., Bradshaw, T. D., Brennan, P., Fegan, C., Wang, S., & Pepper, C. (2014). A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. *Oncotarget, 5*, 375-385.

Wang, I. C., Chen, Y. J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005). Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. *Mol Cell Biol, 25*, 10875-10894.

Wang, I. C., Chen, Y. J., Hughes, D. E., Ackerson, T., Major, M. L., Kalinichenko, V. V., Costa, R. H., Raychaudhuri, P., Tyner, A. L., & Lau, L. F. (2008). FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. *J Biol Chem, 283*, 20770-20778.

Wang, S., & Fischer, P. M. (2008). Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. *Trends Pharmacol Sci, 29*, 302-313.

Wang, S., Griffiths, G., Midgley, C. A., Barnett, A. L., Cooper, M., Grabarek, J., Ingram, L., Jackson, W., Kontopidis, G., McClue, S. J., McInnes, C., McLachlan, J., Meades, C., Mezna, M., Stuart, I., Thomas, M. P., Zheleva, D. I., Lane, D. P., Jackson, R. C., Glover, D. M., Blake, D. G., & Fischer, P. M. (2010). Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. *Chem Biol, 17*, 1111-1121.

Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., Stover, D. G., Lim, E., Wang, Z. C., Iglehart, J. D., Young, R. A., Gray, N. S., & Zhao, J. J. (2015). CDK7-dependent transcriptional addiction in triple-negative breast cancer. *Cell, 163*, 174-186.

Wang, Z. Q., Johnson, C. L., Kumar, A., Molkentine, D. P., Molkentine, J. M., Rabin, T., Mason, K. A., Milas, L., & Raju, U. (2014). Inhibition of P-TEFb by DRB suppresses SIRT1/CK2alpha pathway and enhances radiosensitivity of human cancer cells. *Anticancer Res, 34*, 6981-6989.

Weiss, G. J., Hidalgo, M., Borad, M. J., Laheru, D., Tibes, R., Ramanathan, R. K., Blaydorn, L., Jameson, G., Jimeno, A., Isaacs, J. D., Scaburri, A., Pacciarini,

M. A., Fiorentini, F., Ciomei, M., & Von Hoff, D. D. (2012). Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. *Invest New Drugs, 30*, 2334-2343.

Westerling, T., Kuuluvainen, E., & Makela, T. P. (2007). Cdk8 is essential for preimplantation mouse development. *Mol Cell Biol, 27*, 6177-6182.

Whittaker, S. R., Te Poele, R. H., Chan, F., Linardopoulos, S., Walton, M. I., Garrett, M. D., & Workman, P. (2007). The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. *Cell Cycle, 6*, 3114-3131.

Whittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004). The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. *Cancer Res, 64*, 262-272.

William, A. D., Lee, A. C., Goh, K. C., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Lee, C. P., Wang, H., Williams, M., Sun, E. T., Hu, C., Jayaraman, R., Pasha, M. K., Ethirajulu, K., Wood, J. M., & Dymock, B. W. (2012). Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. *J Med Chem, 55*, 169-196.

Wilson, S. C., Atrash, B., Barlow, C., Eccles, S., Fischer, P. M., Hayes, A., Kelland, L., Jackson, W., Jarman, M., Mirza, A., Moreno, J., Nutley, B. P., Raynaud, F. I., Sheldrake, P., Walton, M., Westwood, R., Whittaker, S., Workman, P., & McDonald, E. (2011). Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. *Bioorg Med Chem, 19*, 6949-6965.

Wong, P., Iwasaki, M., Somervaille, T. C., So, C. W., & Cleary, M. L. (2007). Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. *Genes Dev, 21*, 2762-2774.

Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., Lewis, E. J., McMenamin, R. L., Navarro, E. F., O'Brien, M. A., O'Reilly, M., Reule, M., Saxty, G., Seavers, L. C., Smith, D. M., Squires, M. S., Trewartha, G., Walker, M. T., & Woolford, A. J. (2008). Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. *J Med Chem, 51*, 4986-4999.

Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S. B. (2014). The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. *Mol Cancer Ther, 13*, 2253-2263.

Yanagi, T., & Matsuzawa, S. (2015). PCTAIRE1/PCTK1/CDK16: a new oncotarget? *Cell Cycle, 14*, 463-464.

Yang, J., Zhao, Y., Kalita, M., Li, X., Jamaluddin, M., Tian, B., Edeh, C. B., Wiktorowicz, J. E., Kudlicki, A., & Brasier, A. R. (2015). Systematic Determination of Human Cyclin Dependent Kinase (CDK)-9 Interactome Identifies Novel Functions in RNA Splicing Mediated by the DEAD Box (DDX)-5/17 RNA Helicases. *Mol Cell Proteomics, 14*, 2701-2721.

Yang, L., Zhu, J., Huang, H., Yang, Q., Cai, J., Wang, Q., Zhu, J., Shao, M., Xiao, J., Cao, J., Gu, X., Zhang, S., & Wang, Y. (2015). PFTK1 Promotes Gastric

Cancer Progression by Regulating Proliferation, Migration and Invasion. *PLoS One, 10*, e0140451.

Ye, X., Zhu, C., & Harper, J. W. (2001). A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. *Proc Natl Acad Sci U S A, 98*, 1682-1686.

Yin, J. W., & Wang, G. (2014). The Mediator complex: a master coordinator of transcription and cell lineage development. *Development, 141*, 977-987.

Yokoyama, H., Gruss, O. J., Rybina, S., Caudron, M., Schelder, M., Wilm, M., Mattaj, I. W., & Karsenti, E. (2008). Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. *J Cell Biol, 180*, 867-875.

Zarkowska, T., & Mittnacht, S. (1997). Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases. *J Biol Chem*, *272*, 12738-12746.

Zhang, H. S., & Dean, D. C. (2001). Rb-mediated chromatin structure regulation and transcriptional repression. *Oncogene, 20*, 3134-3138.

Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., Manz, T., Hao, M., Bartkowiak, B., Greenleaf, A. L., Marto, J. A., Geyer, M., Bullock, A. N., Young, R. A., & Gray, N. S. (2016). Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. *Nat Chem Biol, 12*, 876-884.

Zhang, Y. X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., & Wagner, A. J. (2014). Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma *in vitro* and *in vivo*. *Mol Cancer Ther, 13*, 2184-2193.

Zhao, J., Ramos, R., & Demma, M. (2013). CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. *Oncogene, 32*, 3520-3530.

Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X. J., Zhou, J., Sun, Y., Yang, E. S., Liu, L. P., Vaitheesvaran, B., Bridges, L., Kurland, I. J., Strich, R., Ni, J. Q., Wang, C., Ericsson, J., Pessin, J. E., Ji, J. Y., & Yang, F. (2012). Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. *J Clin Invest, 122*, 2417-2427.

Zhou, Y., Han, C., Li, D., Yu, Z., Li, F., Li, F., An, Q., Bai, H., Zhang, X., Duan, Z., & Kan, Q. (2015). Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. *Sci Rep, 5*, 10433.

Zhou, Y., Shen, J. K., Hornicek, F. J., Kan, Q., & Duan, Z. (2016). The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. *Oncotarget*.